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Huntington’s disease (HD) is a neurodegenerative disorder characterized by 
motor disturbance, cognitive decline and psychological dysfunction. Cytoplasmic 
polyadenylation element binding proteins 1-4 (CPEB1-4) are a family of proteins that 
regulate translation of specific mRNAs by modulating their poly(A) tail length. CPEBs 
participate in synaptic plasticity however their role in etiology of neurodegenerative 
diseases has not been studied. Based on different lines of evidence, we reasoned that 
altered CPEB function might contribute to HD.
The first aim of this thesis was to explore the status of CPEBs in HD. We found CPEB1/
CPEB4 imbalance in HD brain and an aberrant poly(A) tail length with concomitant 
alteration of their encoded protein levels. This alteration prominently affects HD-, 
Alzheimer’s- and Parkinson’s disease-related genes. Therefore, CPEB-dependent 
altered polyadenylation becomes a new molecular signature in neurodegeneration 
useful to identify novel effectors like the striatal atrophy-associated gene KTN1 whose 
decreased mRNA-adenylation and protein levels provide a possible explanation for 
HD preponderant striatal affectation.
Strikingly, we noticed that high confidence autism spectrum disorder (ASD) risk 
genes were overrepresented among CPEB4 targets. This finding led us to hypothesize 
CPEB4 as a new hub in ASD gene expression. ASD is a neurodevelopmental disorder 
that manifests in childhood by impaired social communication and restrictive and 
repetitive behaviors. Genetic contribution to ASD resides on risk gene variants that are 
individually minimally penetrant. Since environmental factors also underlie idiopathic 
ASD, it is crucial to identify altered regulators able to orchestrate multiple ASD genes 
along neurodevelopment. 
Thereby, the second aim of this thesis was to study the status of CPEB4 in idiopathic 
ASD patients and to determinate its potential role in ASD risk gene regulation. We found 
that CPEB4 transcripts are mis-spliced in favor of the isoform lacking a neuronal-specific 
microexon in ASD brains. Then, genome-wide polyadenylation analysis revealed a 
new molecular signature of global poly(A) tail shortening with concomitant reduction 
of their protein levels that prominently affects high-confidence ASD genes. Equivalent 
CPEB4-selective splicing isoform-imbalance in mice is sufficient to mimic the mRNA 
polyadenylation and induces ASD-like neuroanatomical, electrophysiological and 
behavioral phenotypes. 
Collectively, these data support a key role of CPEB-mediated altered poly(A) in 
HD and across neurodegenerative diseases and unravel CPEB4 as a new node in ASD 
gene expression.
26
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1. HUNTINGTON’S DISEASE
1.1. First evidence
Huntington’s disease (HD), also known as Huntington’s chorea is a progressive 
neurodegenerative disorder characterized by motor disturbance, cognitive decline 
and behavioral and psychological dysfunction (Vonsattel and DiFiglia, 1998). It is 
inherited in an autosomal dominant manner and affects about 1 in 15,000 individuals 
in North America and Europe (Pringsheim et al., 2012). 
The original descriptions of chorea date from the Middle Ages and it was initially 
named ‘‘Saint Vitus’s dance’’ because affected individuals would dance in circles for 
hours until they dropped from exhaustion (Vale and Cardoso, 2015). But, in 1872 
this chorea was named Huntington’s disease after George Huntington provided the 
classical description (Rub et al., 2015). 
The highest prevalence of HD is found in the people who lives in the Lake 
Maracaibo in Venezuela, and studies in this population led to the identification of the 
genetic change causing HD (Gusella et al., 1983; HDCRG, 1993).
1.2. Mutation
The genetic defect for HD was mapped to the short arm of chromosome 4 (Gusella 
et al., 1983). After an arduous search, the mutation was identified as an abnormal 
expansion of the CAG (Cytosine, Adenine, Guanine) triplet repeats within the coding 
region of the gene “IT15” (Interesting Transcripts 15) also called huntingtin (HTT) 
gene. This mutation produces an expanded stretch of polyglutamine (polyQ) near 
the amino-terminal end (exon 1) (Andrew et al., 1993). In the non-HD population, 
HTT ranges from 9 to 35 CAG copies, with an average median of between 17 and 
20 repeats. However, CAG expansions exceeding 35-40 repeats result in the disease 
(Kremer et al., 1994) (Figure 1A). 
The length of the CAG expansion correlates with severity and it shows strong 
inverse correlation with the age of disease onset (Figure 1B). Juvenile onset is 
associated with HTT carrying about 75 or more repeats (Saudou and Humbert, 2016). 
HD exhibits paternal anticipation, a greater expansion of the trinucleotide repeat with 
paternal transmission (Ranen et al., 1995).
As mentioned, HD is autosomal dominant, but there are rare cases with both 
alleles expanded (homozygous patients). This homozygous mutation does not 
influence age at onset, but disease progression can be more severe (Lee et al., 2012).
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Figure 1: HD mutation in Huntingtin gene. (A) CAG repeat in a healthy and HD gene. (B) Plot from 
HD subjects of known age at neurologic onset. It is plotted the CAG repeat length (x-axis) against 
age of onset (y-axis). The line represents the best-fit simple logarithmic regression to the data 
(Gusella and MacDonald, 2009).
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1.3. Neuropathology
HTT either wild type or mutant (mHTT) is ubiquitously expressed in all cells, but 
main of the changes of HD identified so far occurs in the brain, where intensity of 
the degenerative process differs among specific brain compartments (e.g., striatum, 
cerebral cortex, white matter, hippocampus, thalamus or cerebellum) or systems 
(e.g., basal ganglia or limbic system) (Vonsattel, 2008). 
Degeneration primarily affects the striatum (neuronal loss and gliosis), but other 
regions may also be damaged at early stages, such as the cerebral cortex (Cx). HD 
postmortem brains show degeneration of selective neuronal population, the majority 
of striatal GABAergic medium spiny neurons and, to a lesser extent, cortical pyramidal 
neurons of layers V and VI (Vonsattel and DiFiglia, 1998; Wang et al., 2014). The 
vulnerability of the striatum (St) is associated with the size of the CAG expansion 
(Furtado et al., 1996), and a system for grading severity and evolution of the striatal 
pathology was established (Vonsattel et al., 1985). This classification system for HD 
has five grades (0-4) designated in ascending order of severity.
HD is characterized by the presence of abnormal depositions of huntingtin 
fragments, inclusion bodies (IBs), in the nuclei (Davies et al., 1997) and in the neuropil 
(Gutekunst et al., 1999), that show a fibrillar ultrastructure. The IBs were located in the 
striatum, cerebral cortex, cerebellum, and the spinal cord and they are pathological 
hallmark of HD (Arrasate and Finkbeiner, 2012). Recently rod-like Tau-immunopositive 
deposits also have been discovered along neuronal nuclei (Fernandez-Nogales et al., 
2014).
31
III. INTRODUCTION
1.4. Symptoms
In HD, although the number of CAG repeats is negatively correlated with the age 
of symptom onset (Wexler et al., 2004), there is not a clear correlation with symptom 
profile. Indeed, it has been demonstrated in monozygotic twins that environmental 
factors are important in the phenotypic expression (Gomez-Esteban et al., 2007). 
Now, it is well established that symptoms result from major neurodegeneration in 
both the Cx and basal ganglia (Mehrabi et al., 2016; Thu et al., 2010).
The most characteristic symptoms in HD patients include defects in voluntary 
motor performance, cognitive decline and physiological alterations (Waldvogel et al., 
2012). The most distinctive, well recognized and primary symptom is the development 
of involuntary choreic movements (Huntington, 1872) immediate consequence 
of corticostriatal dysfunction (Estrada-Sanchez and Rebec, 2013). Further, patients 
initially display hyperkinetic movements but they are progressively replaced by 
bradykinesia, rigidity and dystonia (Thompson et al., 1988).
Patients show selective and progressive dysfunction of cognitive capacities, 
impairment in attention, executive function and finally culminate in dementia (Ho et 
al., 2003). The three main neuropsychiatric syndromes include apathy, irritability and 
depression (Thompson et al., 2012). Another hallmark in HD is the weight loss despite 
efforts to maintain a higher caloric intake (Marder et al., 2009).
The most common cause of death of HD patients is primary infectious and 
dysphagia leading to aspiration pneumonia (Heemskerk and Roos, 2012) followed by 
cardiovascular diseases and suicide (Sorensen and Fenger, 1992). 
1.5. Huntingtin
The human HTT gene encodes a 348-kDa multidomain protein with 3142 
aminoacids (UniProt, 2015). The N-terminal region (exon 1) contains the expandable 
polyQ stretch (HDCRG, 1993). In contrast to other exons, exon 1 shows poor 
conservation during evolution (Harjes and Wanker, 2003).
HTT transcripts and protein are ubiquitously expressed but at different levels 
throughout most tissues and, as expected, abundant in the central nervous system 
(CNS) (Marques Sousa and Humbert, 2013). HTT shows a wide distribution at the 
subcellular level being found in nucleus, cytoplasm and dendrites (Trottier et al., 1995), 
and it is associated with endoplasmic compartments, mitochondria, microtubules or 
plasma membrane (Harjes and Wanker, 2003).
32
III. INTRODUCTION
The principal function of HTT is not completely understood, but HTT could be 
considered a multifunctional protein involved in several pathways through its scaffold 
characteristics. This idea is supported by the huge list of HTT-interacting proteins that 
have been identified. These proteins play a role in several processes as endocytosis, 
autophagy, apoptosis, ciliogenesis, cell signaling or transcriptional regulation, 
suggesting that HTT is involved in all of them (Harjes and Wanker, 2003; Saudou and 
Humbert, 2016). Certainly, HTT is essential for embryonic development, as evidenced 
by the facts that knockout (KO) mice die at an early developmental stage (Nasir et al., 
1995), and HTT is important in neurogenesis (Godin et al., 2010).
1.6. Pathogenesis
HTT mutation could induce both loss of function and a gain of toxic function (Liot 
et al., 2016). But, at least 11 inherited neurological disorders are known to be caused 
by CAG expanded repeats encoding a polyQ stretch (SCA1-3, SCA17 or DRPLA). This 
suggests that a toxic gain of function is principally responsible for the disease (La 
Spada and Taylor, 2010). However, the molecular and cellular pathways underlying 
neurodegeneration are still unknown. 
The toxic functions acquired by mutant HTT may involve the full length HTT, 
polyQ short N-terminal fragments (Bates et al., 2015) and also non-polyQ C-terminal 
fragments (El-Daher et al., 2015). In addition, others toxic mechanisms might include 
the accumulation of sense and antisense repeat associated non-ATG (RAN) translation 
proteins (Banez-Coronel et al., 2015), and there is evidence supporting that CAG 
repeat-containing RNA might be directly involved in neurotoxicity (Nalavade et al., 
2013).
Some of the multiple cellular pathways that have been implicated in HD 
pathogenesis include: transcriptional dysregulation (Kumar et al., 2014), excitoxicity, 
vesicular transport (Zuccato et al., 2010), autophagy (Kiriyama and Nochi, 2015) 
or mitochondrial dysfunctions (Liot et al., 2016), ubiquitin–proteasome system 
impairment (Ortega and Lucas, 2014) or splicing alteration (Cabrera and Lucas, 2016; 
Fernandez-Nogales et al., 2014) among others.
1.7. Mouse models
Mouse models of HD mimic many aspects of the human disease. These transgenic 
(Tg) mice are powerful tools that let us advance in our understanding of disease, and 
also evaluate efficacy of potential new treatments. It is important to question what 
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mouse model should to be used (Ehrnhoefer et al., 2009; Menalled and Brunner, 
2014). Tg mouse models can be divided into three categories depending on how they 
were engineered: 
- Exon 1 Tg models express N-terminal fragment of human HTT gene with expanded 
CAG repeat. For example, R6/1-2 mice (Mangiarini et al., 1996) are the most widely 
used because they have a robust phenotype and early onset, or HD94 conditional 
Tg mice which display conditional expression of a similar transgene (Yamamoto et 
al., 2000).
- Full-length Tg models express the polyQ mutation in the full-length human HTT 
gene. Some examples are YAC128 and BACHD mice that carry yeast or bacterial 
artificial chromosome (Gray et al., 2008; Slow et al., 2003). 
- Knock-in models have the CAG sequence inserted into the endogenous mouse Htt 
gene, as for example zQ175 (Menalled et al., 2012) that present a relatively slow 
progression of phenotype.
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2. AUTISM SPECTRUM DISORDER
2.1. Definition
Autism spectrum disorder (ASD) is the most common neurodevelopmental 
disorder that manifests during early childhood (DSM-V, 2013). Symptoms are most 
marked during infancy and many individuals improve with age (Delorme et al., 2013; 
Jones et al., 2014). ASD comprises different phenotype outcomes and ages of onset, 
but the actual ASD diagnostic criteria is defined (DSM-V, 2013) as follows: 
- Persistent deficits in social communication and interaction; deficits in social-
emotional reciprocity, nonverbal communicative and developing relationships.
- Restricted, repetitive patterns of behavior, interests, or activities.
Other comorbidities such as intellectual disability, language impairment, 
microcephaly or craniofacial dysmorphology (Stessman et al., 2016), epilepsy 
(Tuchman and Rapin, 2002), motor deficiencies (Setoh et al., 2016) or anxiety (White 
et al., 2009) are frequent in ASD subjects.
ASD has a prevalence of about 1 in 160 people worldwide (Elsabbagh et al., 2012) 
and it is interesting to note that it is more common in males than in females, with a 
ratio of 4:1 (Van Wijngaarden-Cremers et al., 2014).
The causes and pathogenic mechanisms of ASD remain unknown. Although it is 
highly heritable, strong evidence indicates that the causes include both genes and 
environmental factors (Geschwind and State, 2015).
2.2. Syndromic vs. non-syndromic 
ASD can be classified in syndromic and non-syndromic, a distinction that is 
exclusively based on clinical criteria (Sztainberg and Zoghbi, 2016).
Syndromic is used to describe cases where ASD diagnosis is secondary to an 
existing condition with additional phenotypes and/or dysmorphic features. The 
etiology is usually known and can involve chromosomal abnormalities, copy number 
variations (CNV) or mutations in a single gene with high penetrance for ASD, such as 
in Fragile X syndrome (FXS) (Verkerk et al., 1991), Angelman syndrome (Donlon, 1988) 
or Rett syndrome (Amir et al., 1999).
The term non-syndromic is used in cases where ASD is the primary diagnosis 
and no additional symptoms are present, typically referred to as “idiopathic autism”. 
Although in most of the cases, the etiology is unknown, cumulative evidence has 
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proven that there is a genetic factor involved (Baudouin et al., 2012; Sztainberg and 
Zoghbi, 2016). 
2.3. Genetics
ASD is a multigenic disorder, which is highly heritable as evidenced by studies 
on the recurrence risk in families and twins (Sandin et al., 2014). Using traditional 
genetic approaches, over 100 genes have been identified that contribute to idiopathic 
ASD risk. These monogenic disorders are rare, and together they are estimated to 
represent ∼5% of ASD cases, for example, NLGN3-4 (Jamain et al., 2003) or FOXP1 
(Hamdan et al., 2010). 
Whole-genome microarray studies allowed the identification of copy number 
variants, such as duplications and deletions (Sebat et al., 2007). They affect many 
loci and contribute to other ∼5% of ASD cases (Abrahams and Geschwind, 2008; 
Betancur, 2011). More recently, the whole-exome sequencing on large ASD cohorts 
has revolutionized gene discovery. These studies have pinpointed about 120 new ASD 
risk genes with de novo coding single nucleotide variants (SNVs) and de novo insertion 
deletions (indels) (De Rubeis et al., 2014; Iossifov et al., 2014).
Overall, according to current estimates, perhaps more than 1000 risk genes are 
likely to be involved in ASD (De Rubeis and Buxbaum, 2015; Geschwind and State, 
2015; Willsey and State, 2015). The entire database of known genes with a risk factor 
linked to ASD can be found in Simons Foundation Autism Research Initiative (SFARI) 
website (http://sfari.org/).
2.4. Environment
Although genetic mutations contribute to a sizeable amount of occurrences of 
ASD, recent estimates suggest that 50–60% of the risk of ASD is unaccounted for, 
which implies that environmental factors contribute substantially to the risk of this 
disorder (Estes and McAllister, 2015) (Figure 2). Consistent with this idea is the fact 
that almost all genetic risk factors for ASDs can be found in unaffected individuals 
(Robinson et al., 2016) and twin studies equally provided evidence for genetics and 
environmental factors in ASD risk (Sandin et al., 2014). 
A wide range of environmental factors have been proposed to contribute to ASD 
causality (Grabrucker, 2012; Homberg et al., 2016). The list, which is expanding given 
our greater understanding of the disorder, according to most up-to-date research 
includes the following factors: 
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- Pre-natal: Failures in early fetal brain development have been linked to a higher 
risk of ASD, for instance, maternal nutrient deprivation, toxins (Negi et al., 2010), 
stress (Kinney et al., 2008), maternal immune activation (MIA) by infection or 
autoimmune disease (Estes and McAllister, 2016; Ornoy et al., 2015). 
- Post-natal: Brain development lasts throughout adolescence and many factors can 
hinder this process, for instance, gut microbiome (Sharon et al., 2016) immune 
system abnormalities, allergies, infection (Estes and McAllister, 2015) and exposure 
of children to drugs or toxins (Yasuda et al., 2011).
Alzheimer's disease
Major depressive disorder
Bipolar disorder
Schizophrenia
Obsessive-compulsive disorder
Attention-deficit/hyperactivity disorder
Autism spectrum disorder
Intellectual disability (mild)
Intellectual disability (severe)
Additive genetic
Shared environment
Genetic vs. environmental contribution
Proportion of liability (%)
Other/non-shared
environment
0 20 40 60 80 100
Figure 2: Genetic and environmental contribution to liability for neuropsychiatric disease. Liability 
estimates are compiled for various neuropsychiatric disorders (ASD in bold) derived from large-
scale twin and/or population-based studies (Gandal et al., 2016).
Overall, it appears likely that in the majority of cases, genetic risk entails a 
predisposition to ASD, while its actual onset requires a further environmental reason 
(Nardone and Elliott, 2016). Therefore, it is essential to identify in idiopathic ASD 
altered regulators, able to orchestrate the expression of multiple ASD susceptibility 
genes along normal and altered neurodevelopment.
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3. CPEB-MEDIATED TRANSLATIONAL CONTROL
3.1. mRNA processing and translational control
mRNA translational control in eukaryotic cells allows rapid alteration of protein 
concentrations for maintaining homeostasis or modulating changes (Buffington et al., 
2014). Gene expression begins with the synthesis of mRNA (pre-mRNA) from the DNA 
template by RNA polymerase II. The path from transcription to translation includes 
many steps of regulation that make crucial contributions to accurate gene control 
(Huang et al., 2015; Jarvelin et al., 2016). They can be summarized: 
mRNA processing: maturation often occurs during mRNA synthesis in the nucleus 
(Bentley, 2014; Darnell, 2013). This process include: capping; a 7‑methylguanosine 
cap to the 5ʹ (Ramanathan et al., 2016), splicing; the removal of introns and ligation 
of exons (Alpert et al., 2016) and formation of a 3ʹ end by cleavage and addition of a 
poly(A) tail; polyadenylation (Di Giammartino et al., 2011).
Transport: mature mRNA associate with a wide variety of proteins to make a 
particle called, messenger ribonucleoproteins (mRNPs) (Bentley, 2014). This particles 
are competent for export to the cytoplasm by nuclear pore complexes (Katahira, 
2015).
Translation: once in the cytoplasm, mRNAs are circularized, and they are the 
common target of translational control (Weill et al., 2012). mRNA translation can be 
divided in three regulated phases:
- In the initiation, the ribosomes bind to the mRNA and scan the 5’ untranslated 
region (UTR) until they find the initiation AUG start codon. Most regulation is 
exerted at this first stage (Sonenberg and Hinnebusch, 2009).
- Then, polypeptide chain is elongated. Despite the simplicity of elongation, 
regulation can and does occur (Richter and Coller, 2015).
- Finally, termination occurs in response to a stop codon and the polypeptide chain 
is released from the mRNA and ribosome, whose recycling is controlled. (Jackson 
et al., 2012).
3.2. Translation control by changes in poly(A) tail length
In the nucleus, most of mRNAs acquire a non-templated poly(A) tail of 250–300 
adenine residues, fundamental for mRNA stability and nuclear export. The pre-
mRNA includes cis-acting regulatory sequences and auxiliary trans-acting factors 
that indicates specific poly(A) site (PAS) (Curinha et al., 2014). The most important 
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cis-element is the conserved hexanucleotide (Hex), mainly consisting of AAUAAA or 
AUUAAA located 10–30 nucleotides upstream of the PAS (Shi and Manley, 2015).
In the cytoplasm, poly(A) tail acts synergistically with the 5′ cap to facilitate 
translation initiation. Nuclear polyadenylation occur by default, but subsequent 
control of its length is highly regulated both in the nucleus and in the cytoplasm, 
thereby contributing to the regulation of the stability, transport and translation (Weill 
et al., 2012). Thus, many mechanisms and factors involved in regulating nuclear and 
cytoplasmic polyadenylation have been identified:
Alternative polyadenylation (APA) is a widespread mechanism that allows 
a single gene to encode multiple mRNA transcripts. Pre-mRNAs, are cleaved and 
polyadenylated in more than one site, thus generating 3′ UTRs of different lengths (Di 
Giammartino et al., 2011).
Deadenylation can be followed by decapping and mRNA degradation (Parker 
and Song, 2004). However transcripts with short poly(A) can also be stable but in a 
translationally silent state that can be reactivated by cytoplasmic polyadenylation 
(Weill et al., 2012; Zhang et al., 2010).
3.3. Cis-tras -acting element in polyadenylation
Regardless of the final outcome, whether mRNA degradation or translational 
silencing o reactivation, de- or poly-adenylation is carried out through a complex 
combinatorial arrangement of cis-acting regulatory sequences. These sequences are 
specifically recognized and regulated by a large number of trans-acting factors, which 
can be RNA-binding proteins (RNABP) or noncoding RNAs. Most of these regulatory 
sequences reside in the 3’ untranslated region (UTR) but they are also present in the 
5′ UTR or even in the open reading frame (ORF) (Charlesworth et al., 2013; Weill et 
al., 2012). For example:
AU-rich elements (ARE) consisting mainly of AUUUA pentamer repeats, which 
are recognized by different ARE-binding proteins such as TTP or ELAV1 (Khabar, 2016).
Pumilio-binding sites are sequences in the 3′ UTR containing a conserved UGUR 
(R is a purine) sequence which are recognized by Pumilio and FBF (PUF) family 
members (Wang et al., 2013).
Cytoplasmic polyadenylation elements (CPE) consisting of the UUUUA
1-3
U 
sequence and they are recognized by the CPE binding (CPEB) proteins (Villalba et al., 
2011).
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3.4. CPEB-family of proteins
The cytoplasmic polyadenylation element binding (CPEB) proteins are RNABPs 
which regulate the length of the poly(A) tail and the pseudocircularization of the 
mRNA (Fernandez-Miranda and Mendez, 2012).
The CPEB-family of proteins is composed of four paralogs in vertebrates (CPEB1-
4), where CPEB1 constitutes a distant branch of the family and CPEB2-4 are closely 
related each other (Wang and Cooper, 2010). CPEB orthologs are present in other 
species but in different numbers, such as Orb 1-2 in Drosophila (Stepien et al., 2016), 
cpb1-3 and fog-1 in C. elegans (Lamont and Kimble, 2007) or CPEB in Aplysia (Si et al., 
2003b). Exon structures of CPEB orthologs among vertebrates are almost identical, 
and the phylogenetic tree clearly demonstrated that they are better conserved 
across species than across paralogs (Wang and Cooper, 2010) (Figure 3). This high 
conservation between species indicates that natural selection operates against the 
deleterious effects of allelic variants (Omer et al., 2016). 
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Figure 3: CPEB family of RNA-binding proteins. Phylogenetic tree of the most representative CPEB 
proteins based on a multiple sequence alignment using complete protein sequences. CPEB1 in 
vertebrate (yellow) is the most distant member of the family. However, CPEB2-4 (blue) are closely 
related and placed in the same branch. Modified from Fernandez-Miranda and Mendez, 2012.
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All CPEB proteins have a similar structure. The carboxyl-terminus domain 
is conserved in all CPEB proteins, it is composed by two RNA recognition motifs 
(RRMs) and two zinc-finger (ZnF) like motifs (Tsuda et al., 2014). The N-terminal is 
a regulatory domain which is highly variable among CPEBs (Fernandez-Miranda and 
Mendez, 2012) (Figure 4). A number of reports have shown that CPEBs may bind the 
same mRNAs, both in vertebrates (Novoa et al., 2010) and in Drosophila (Stepien et 
al., 2016). mRNAs require two cis-acting sequences in the 3’UTR to recruit CPEBs, the 
conserved Hex and the nearby consensus or non-consesus CPE sequences (Pique et 
al., 2008). This suggests that different CPEBs may act differently at the regulation of 
the same transcripts. 
3.5. Regulation of CPEB levels and activities
Up to 30%-40% of genes have functional CPEs and be CPEB-regulated although 
in different spatiotemporal patterns. CPEBs have dual functions as translational 
activators (poly(A) elongation) or repressors (stored mRNA in a silent state) (Figure 
5). Furthermore, the CPEs define a combinatorial code, based on their number and 
distance to the PAS, as well as the presence of additional cis-acting elements, to 
determine the spatiotemporal translation pattern (Pique et al., 2008). 
Moreover, CPEBs are subjected to different regulatory signals. CPEB1 is 
phosphorylated by Aurora kinase A, CDC2 (Mendez et al., 2002; Mendez et al., 
2000) and Ca2+/calmodulin-dependent protein kinase II (CaMKII) (Atkins et al., 2005; 
Atkins et al., 2004), while CPEB4 activity is regulated by ERK2 and CDK1-mediated 
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Figure 4: Structural comparisons among CPEBs from several species. CPEBs share a conserved RRMs 
(RNA recognition motifs) and zinc-fingers (ZnFs) at the C-terminal. PolyQ refers to polyglutamine 
rich stretches. The percent identities refer to comparisons relative to Xenopus CPEB1. Modified 
from Ivshina et al., 2014.
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phosphorylation. Unphosphorylated CPEB4 sequesters CPE-containing mRNAs into 
inactive liquid-like droplets but when it is hyperphosphoryated CPEB4 is kept in a 
monomeric and active state (Guillen-Boixet et al., 2016). 
On the other hand, CPEB3 is regulated by SUMOylation (Drisaldi et al., 
2015), phosphorylation (Kaczmarczyk et al., 2016), and by Neuralized1-mediated 
monoubiquitination (Pavlopoulos et al., 2011) apart from being degraded by Calpain2 
(Wang and Huang, 2012). 
Repressed mRNA Activated mRNA
5’ Cap
HexCPE
CPEB
AAAA
5’ Cap
HexCPE
CPEB
AAAAAAAAAAA
Activation
Translation
iniciation factors
Poly(A)
binding
proteins
Figure 5: CPEB-mediated translational repression and activation. CPEB proteins are shown as a 
circle and CPE and the Hex sequences are indicated as a square and hexagon, respectively. 
Binding of CPEBs to CPEs induce the formation of a repressed closed-loop of mRNA. When CPEBs 
are activated (red star) promote cytoplasmic polyadenylation resulting in efficient translation.
Also, CPEBs autoregulate themselves or by other CPEB, for example CPEB4 
is translationally activated by CPEB1 (Igea and Mendez, 2010) and by a feed-back 
loop (Calderone et al., 2016). In addition, all CPEBs express more than one isoform 
generated by alternative splicing. These different variants affect both the ORFs and the 
UTRs and are evolutionarily conserved (Theis et al., 2003; Wang and Cooper, 2010). 
Different isoforms vary their regulation, functions, and even their tissue specificity 
(Johnson et al., 2015; Kaczmarczyk et al., 2016; Skubal et al., 2016). Thus, increasing 
the level of complexity in translational control exerted by the CPEB-family. 
Apart from their well described role in cytoplasmic poly(A) tail length regulation, 
CPEBs have been also implicated in nuclear functions. All CPEB proteins shuttle 
to the nucleus (Kan et al., 2010). There, CPEB1 mediates pre-mRNA alternative 
polyadenylation site and alternative splicing (AS) (Bava et al., 2013; Lin et al., 2010), 
and CPEB4 nuclear accumulation is correlated with reduced programmed cell death 
in response to endoplasmic reticulum stress (Kan et al., 2010).
3.6. CPEB-mediated processes and pathways 
In addition to the well established role of CPEBs in oogenesis, they regulate many 
biologicals processes (Ivshina et al., 2014).
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Cell proliferation, senescence and cancer. CPEBs are very important for meiotic 
and mitotic temporal translational control (Kim et al., 2011; Novoa et al., 2010). 
Surprisingly, despite their proliferative function, they also can induce senescence 
(Burns et al., 2011; Xiaoping et al., 2013). Finally, CPEBs has been linked to tumor 
growth, invasiveness or angiogenesis, however, different CPEBs appear to play diverse 
roles in cancer, as tumor suppressors or oncogenic effects (Chen et al., 2016; Nagaoka 
et al., 2016; Ortiz-Zapater et al., 2011). 
Metabolism. Evidence linking CPEB1 and CPEB4 to metabolism has been 
reported. CPEB1-deficient human fibroblasts show enhance rates of glycolysis (Burns 
and Richter, 2008) and CPEB1 KO display aberrant glucose metabolism (Alexandrov 
et al., 2012) and deficient brain mitochondrial ATP production (Oruganty-Das et al., 
2012). Recently, it was found that CPEB4 is required for adaptation to high-fat-diet- 
and ageing induced endoplasmic reticulum stress (Maillo et al., 2017).
Development. CPEBs have been studied in depth in oocyte maturation (Reyes 
and Ross, 2016), and have been demonstrated that they play important role in 
Drosophila (Hafer et al., 2011), C.elegans (Kimble and Crittenden, 2007) and also 
mouse development (Sousa Martins et al., 2016) with CPEB4 being expressed at high 
levels in the developing brain and spinal cord (Shin et al., 2016; Theis et al., 2003). 
3.7. CPEB functions in the nervous system
The four CPEB paralogs are widely expressed in brain (Lein et al., 2007; Theis 
et al., 2003) where they play important roles. Proof of this is that all KO mice of 
each CPEB show neurological alterations. CPEB1 KO mice show perseverative 
hippocampal-dependent memory and defects in long-term potentiation (Alarcon et 
al., 2004; Berger-Sweeney et al., 2006). CPEB2 KO mice show alteration of cholinergic 
neurons (Lai et al., 2016). CPEB3 KO mice exhibit enhanced hippocampal-dependent 
short-term memory (Chao et al., 2013). Finally, CPEB4 KO pyramidal neurons possess 
slightly elongated dendritic spines (Tsai et al., 2013).
3.7.1. CPEBs in synaptic plasticity
The implication of CPEBs in synaptic plasticity is well known. Synaptic plasticity is 
the term applied to the ability of synapses to undergo morphological and biochemical 
changes in response to stimulation. Neurons have the capacity to distinguish between 
synapses that have been stimulated (experienced) versus those that have not (naïve) 
(Ivshina et al., 2014; Richter, 2007). 
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Many forms of long-term synaptic plasticity require local protein synthesis in 
the post-synaptic compartment (Sutton and Schuman, 2006). CPEB1 associates with 
kinesin and dynein that transport mRNAs to dendrites (Huang et al., 2003). Also, 
CPEBs and other components of cytoplasmic polyadenylation machinery are present 
in dendrites (Udagawa et al., 2012; Wu et al., 1998) where they trigger mRNA-specific 
polyadenylation and local translation (Huang et al., 2006; Pavlopoulos et al., 2011). 
The half-life of newly synthesized proteins is short and it cannot explain the 
persistence of synaptic plasticity. Some groups suggested that CPEB, at least in Aplysia 
(Si et al., 2010) and Drosophila (Khan et al., 2015) might form a prion in neurons 
and be self-propagated and extremely long-lived, thus constituting a tag at activated 
synapses. This is possible because Aplysia CPEB (Si et al., 2003a; Si et al., 2003b), 
Drosophila Orb2 (Majumdar et al., 2012) and mammaliam CPEB3 (Stephan et al., 
2015) contain a prion-like poly Q/N-rich regions and form amyloid-like aggregates 
that would act as prions.
3.7.2. CPEBs and neurological disease
There is no evidence of CPEBs being directly implicated with in neurological 
disease. However, a mouse model that expresses an artifactual (or aberrant) low 
complexity domain of CPEB4 protein shows impaired motor axon branching and 
abnormal neuro-muscular formation suggesting a potential implication of CPEB4 in 
neurodevelopmental disease (Shin et al., 2016).
Also, FMRP (fragile-X mental retardation protein) KO mice show fragile X 
syndrome (FXS) features that are rescued in FMRP/CPEB1 double KO mice (Udagawa 
et al., 2013). FXS is a monogenic form of autism that it is caused by inactivation of 
the FMR1 gene (Verkerk et al., 1991). In the absence of FMRP, protein synthesis is 
elevated by 15–20%, which is likely causative for the syndrome (Darnell and Klann, 
2013). The protein synthesis in double FMRP/CPEB1 KO mice is normal suggesting 
that translational homeostasis was restored (Udagawa et al., 2013). 
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4. EVIDENCE LINKING CPEBS TO NEUROLOGICAL DISEASE
4.1. CPEBs and HD
We reasoned that altered CPEB function might contribute to HD based on the 
following evidence: 
First. Spinocerebellar ataxia type 3 (SCA3) is the most common dominantly 
inherited ataxia and it is caused by CAG repeat expansion (encoding polyQ) in ATXN3 
gene (Ikeda et al., 1996). Genome-wide screen for suppressors or enhancers of 
pathogenic polyQ Ataxin-3 in a Drosophila SCA3 model showed that overexpression 
of orb2 (CPEB2-4 ortholog) is a suppressors of retinal degeneration (Bilen and Bonini, 
2007). A later study showed that upregulation of orb2 rescued abnormal wing posture 
and locomotor defects and ameliorates the retina degenerative effect of SCA3 fly 
models (Shieh and Bonini, 2011).
Second. Interestingly, CPEB3, Drosophila orb2 and Aplysia CPEB, contain a polyQ 
domain that confer them prion-like properties (Majumdar et al., 2012; Raveendra et 
al., 2013; Stephan et al., 2015) important for the maintenance of long-term memory 
(Khan et al., 2015; Si et al., 2010).
Third. Several studies have linked brain-derived neurotrophic factor (BDNF) and 
HD with major loss of BDNF protein in HD brain probably contributing to the clinical 
manifestations of the disease (Zuccato and Cattaneo, 2014). In cultured neurons it 
was found that BDNF mRNA is associated with HTT and CPEB1 (Ma et al., 2010). BDNF 
mRNA has two cis-acting CPE motifs in its 3’UTR (Oe and Yoneda, 2010) and they are 
required for dendritic targeting by binding to CPEB1 (Baj et al., 2016; Vicario et al., 
2015).
Forth. Microarray and gene ontology (GO) differential analysis of mRNAs 
associated with polysomes in wild type (WT) and CPEB1 KO mouse embryonic 
fibroblasts revealed that HD related genes are prevalent among those mistranslated 
in the absence of CPEB1 (Alexandrov et al., 2012). 
Fifth. mRNAs associated with CPEB4 were previously identified by RNA 
immunoprecipitation (RIP) from human pancreatic cancer cells (RWP-1) (Ortiz-
Zapater et al., 2011) and by GO analysis we found that HD related genes as the second 
category both in number and significance (Figure 6). 
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4.2. CPEBs and ASD
In view of these lines of evidence linking CPEB and HD, the first aim of this thesis 
was to explore the status of CPEBs in HD and the potential genome-wide poly(A) 
tail changes of target mRNAs. Strikingly, this serendipitously led us to discover that 
most autism risk genes are targets of CPEB4, which originated the corresponding 
hypothesis that CPEB4 could be implicated in ASD etiology. Indeed, this fits with the 
fact that CPEB4 is expressed at high levels in developing brain (Shin et al., 2016; Theis 
et al., 2003). 
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Figure 6: GO analysis of CPEB4 targets from RWP-1 cells. Gene count histogram from gene 
ontology using DAVID functional analysis of CPEB4 coimmunoprecipitated mRNAs from RWP-1 cells 
(Ortiz-Zapater et al., 2011). Total number of annotated genes per category represented under bars. 
Significative p-values and Benjamini-Hichberg in italic, above the bars.
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IV. OBJETIVES
1. Analysis of CPEBs in human and mouse HD brain. 
2. Analysis of global poly(A) tail changes in R6/1 mouse model of HD.
3. Determine the relative contribution of CPEB1 and CPEB4 to poly(A) changes 
in HD and find CPEB dependent pathways and gene modules.
 Then, unbiased observation of enrichment of ASD risk genes within CPEB4-
regulated transcripts, originated the following:
4. Study the possible alteration of CPEB4 in idiopathic ASD brain and its 
potential pathological implication.
5. Generation of different mouse models that mimic the CPEB4 alterations 
found in idiopathic ASD for subsequent poly(A) analysis.
6. Characterize ASD-like phenotype in CPEB4-modified mouse models.
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V. RESULTS
1. ANALYSIS OF CPEBS IN HUMAN AND MOUSE HD BRAIN
1.1. Analysis of protein and mRNA levels of CPEBs in HD brain
To determine whether misregulation of CPEBs could contribute to HD, we first 
analyzed their levels by western blot in postmortem brain samples from human 
control and HD subjects. In St, the most affected region in HD, we observed a dramatic 
increase (453%, p=0.037) of CPEB1 and an almost total disappearance of CPEB4 
(83% decrease, p=0.001), but no significant changes in the levels of CPEB2 or CPEB3 
proteins (Figure 7).
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Figure 7: Western blot analysis of CPEBs in human St. Levels of CPEB1, CPEB2, CPEB3 and CPEB4 
protein in controls (n=4-5) and HD patients (n=5-6) striatum. Data are shown as mean ± SEM. * p < 
0.05, *** p < 0.001.
We then analyzed the R6/1 transgenic mouse model of expanded CAG/polyQ 
disease that ubiquitously expresses N-terminal Htt with 115 CAG repeats and develops 
a rapidly progressing disease phenotype (Mangiarini et al., 1996). As for human HD 
brain, we observed increased CPEB1 (159%, p=0.018) and decreased CPEB4 (35% 
decrease, p=0.04) levels in St of R6/1 mice with no significant changes in the levels of 
CPEB2 or CPEB3 (Figure 8).
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Figure 8: Western blot analysis of CPEBs in R6/1 mice St. Levels of CPEB1, CPEB2, CPEB3 and CPEB4 
protein in WT (n=7) and R6/1 mice (n=7) striatum. Data are shown as mean ± SEM. * p < 0.05.
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Similar results were observed in St of the slow disease progression HD94 mice 
(Figure 9A) that express N-terminal Htt with 94 CAG repeats in forebrain neurons 
(Diaz-Hernandez et al., 2005; Yamamoto et al., 2000). However, in HD94 mice and in 
the also slow disease progression zQ175 knock-in mouse model of HD (Menalled et 
al., 2012), only the decreased CPEB4 levels reached statistical significance (Figures 
9A-B), thus suggesting that changes in CPEB4 might precede changes in CPEB1. 
In general, the described imbalance in CPEB1/CPEB4 protein levels in St of HD 
patients and R6/1 mice did not correlate with matching alterations of their transcript 
levels (Figures 10A-B).
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Figure 9: Western blot analysis of CPEBs in St of HD mouse models. Levels of CPEB1 and CPEB4 
protein, (A) in WT (n=8) and HD94 mice (n=6), (B) in WT (n=6) and zQ175 mice (n=6) striatum. Data 
are shown as mean ± SEM. * p < 0.05. ** p<0.01.
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Figure 10: qRT-PCR analysis of CPEBs in St of HD patients and R6/1 mice. mRNA levels of CPEB1, 
CPEB2, CPEB3 and CPEB4 (A) in human (n=5 for control and n=9 for HD patients) and (B) mouse (n=7 
for WT and R6/1 mice). Data are shown as mean ± SEM. * p < 0.05.
Conclusion: St from HD patients and mouse models showed a CPEB1/CPEB4 
imbalance, being CPEB1 levels increased and CPEB4 decreased. These protein levels 
do not correlate with transcripts levels, suggesting a posttranscriptional regulation.
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1.2. Analysis of pattern of CPEBs in HD brain
In good agreement with its RNP activity, CPEB4 is found in a cytoplasmic punctate 
pattern in mouse brain tissue. When we compared WT and R6/1 mice, the St decrease 
in CPEB4 levels was also evident in R6/1 mice (Figure 11). 
 
However, we did not found evidence of CPEB4 was sequestered into the 
characteristic polyQ-containing IBs of HD tissue (Figure 12). 
R6/1WT
CPEB4
50μm 50μm
Figure 11: CPEB4 pattern in mouse St. CPEB4 expression determined by immunohistochemistry in 
sagittal sections of WT and R6/1 mice St. The scale bar indicates 50 μm.
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Since CPEB3 is specifically known to aggregate through its Q-rich N-terminal 
domain, we also performed immunostaining for CPEB3 both in human HD and R6/1 
tissue and controls. This revealed similar CPEB3 level and distribution between HD 
and control samples and no accumulation into IBs (data not shown). 
Conclusion: CPEB4 level by IHC shows a dramatic decrease in R6/1 St and no evidence 
of any of the CPEBs being sequestered in characteristic IBs of HD mice.
Figure 12: CPEB4 is not sequestered in HD inclusion bodies. Double Immunofluorescence with 
antibodies to CPEB4 (green), and HTT IBs (red) in sagittal sections of WT and R6/1 mice St.
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2. ANALYSIS OF GLOBAL POLY(A) CHANGES IN R6/1 MOUSE MODEL OF HD
2.1. Genome-wide poly(A) alteration by poly(U) chromatography and 
microarray analysis
The main function of CPEBs is to regulate the cytoplasmic polyadenylation. To 
explore whether altered CPEBs levels in HD resulted in polyadenylation alteration of 
target mRNAs, we analyzed genome-wide the poly(A) tail length changes associated 
with HD in the R6/1 mouse model. For this, we performed poly(U) chromatography 
on RNA purified from St of WT and R6/1 mice. Differential elution with 25 and 90% 
formamide yields two fractions of RNAs with, respectively, short and long poly(A) tails 
which were analyzed by microarray hybridization (Figure 13). 
Altogether, transcripts of 3,968 genes are differentially polyadenylated in R6/1 
vs. WT mice: 1,980 transcripts whose poly(A) tails get shortened and 1,988 transcripts 
whose poly(A) tails get lengthened in R6/1 mice (Figures 14A-B).
R6/1
Total RNA extraction (St)
poly(A) RNA purification
55ºC
25% formamide
A
A
A
AA
Washed
Short poly(A) tail 
fraction
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90% formamide
AAAA...
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AAAAAAA...
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Long poly(A) tail 
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Microarray analysis / mRNA identification
pool (n=4)  
Input
Total RNA
Poly(U) chromatography
WT
poly(U) 
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Figure 13: Chromatography and microarray analysis. Schematic view of the procedures for the 
poly(U) chromatography experiment from St of WT and R6/1 mice 7 month-old.
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The gene with the most extreme poly(A) tail shortening in HD mice is autism 
susceptibility candidate 2 (AUTS2) (Figure 14B). We then tested whether this 
correlates with altered protein levels in St of R6/1 mice. As expected, AUTS2 protein 
levels show a strong decrease in St of R6/1 mice without changes at the mRNA level 
(Figures 15A-B) and similar results were obtained with human striatal tissue samples 
from control and HD cases (data not shown). Among the genes with most prominent 
poly(A) tail elongation in R6/1 St, we analyzed syntaxin 6 (STX6) (Figure 14B) and we 
found a significant increase in its protein levels in the St of R6/1 mice that does not 
correlate with increased transcript levels (Figures 15A-B). 
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Figure 14: mRNA with most extreme poly(A) tail changes in R6/1 mice. (A) Pie chart of differentially 
polyadenylated transcripts, shortened (red) or lengthened (blue), in R6/1 mice. (B) Transcripts 
whose poly(A) tail is shortened (f.c. ≤ -4.5) or lengthened (f.c. ≥ 4.5) in St of R6/1 vs. WT mice. In 
yellow, genes for which poly(A) tail alteration correlates with altered protein levels as verified by 
western blot. In orange, gene identified by data mining as linked to striatal atrophy.
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Figure 15: Western blot and qRT-PCR analysis of genes with the most extreme poly(A) tail changes 
in R6/1 mice. (A) Levels of AUTS2 and STX6 protein (n=7 for WT and R6/1 mice). (B) mRNA levels of 
for Auts2 and Stx6 (n=7 for WT and R6/1 mice). Data are shown as mean ±SEM. * p < 0.05, **p<0.01.
Conclusion:  St of R6/1 mice shows a global transcriptomic poly(A) tail length alteration 
with 9.42% genes showing deadenylation and 9.46% elongation. The most affected 
transcripts show a concomitant change in the corresponding protein levels without 
changes in mRNA level. This suggests that CPEB1/CPEB4 imbalance impacts global 
poly(A) status which is associated to protein changes in St of R6/1 mice.
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2.2. GO analysis of transcripts with poly(A) tail altered in R6/1
To explore whether the observed changes in poly(A) length in affected genes 
might be contributing to HD pathogenesis, we performed GO analysis on the 1,844 
genes with poly(A) fold change (f.c.) above 2. This confirmed the expected enrichment 
in HD related genes anticipated by the enrichment observed for CPEB4 binding 
transcripts in pancreatic cancer cells, (Figures 6 and 16A). Strikingly, we also observed 
an even more significant enrichment for Alzheimer’s disease (AD) related genes and 
also significant enrichment for Parkinson’s disease (PD), as well as ubiquitin mediated 
proteolysis genes (Figures 16A-B). 
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Figure 16: GO analysis of transcripts with poly(A) tail altered in R6/1 reveals neurodegeneration 
affected genes. (A) Gene count histogram from GO analysis using DAVID resources of mRNAs with 
changes in poly(A) tail length in R6/1 mice (f.c. ≤ -2 or ≥ 2). Total number of annotated genes per 
category represented under bars. Significative p-values and Benjamini-Hichberg in italic, above the 
bars. (B) Venn diagram of transcripts implicated in neurodegenerative diseases whose poly(A) tails 
are significantly shortened or lengthened in R6/1 (f.c. ≤ -1.5 or ≥ 1.5). Grey circle represents AD, blue 
HD and pink PD related genes.
Interestingly, among the 240 AD, HD and/or PD related genes that generate 
transcripts with altered poly(A) tail in R6/1 mice, many correspond to genes 
responsible for monogenic forms of familial neurodegenerative diseases such as 
Psen1, Mapt, Scna, Lrrk2, Pink1, Park7, Sod1 and Htt itself (Hardy and Gwinn-Hardy, 
1998; Klein and Westenberger, 2012). As well as to other genes highly implicated in 
HD pathogenesis such as Bdnf (Zuccato and Cattaneo, 2009) and in AD pathogenesis 
such as Ide (Nalivaeva et al., 2014) and Gsk3β which is involved in both diseases 
(Fernandez-Nogales et al., 2015; Hernandez et al., 2013) (Figure 16B). 
Most importantly, lengthened poly(A) tail in transcripts of the AD related gene 
Mapt in R6/1 mice correlates with increased protein levels as previously described 
(Fernandez-Nogales et al., 2014). Similarly, shortened poly(A) tail in Gsk3β transcript 
corresponds to decreased protein levels as also showed (Fernandez-Nogales et 
al., 2015). Regarding PD related genes, shortened poly(A) tail in Snca transcript 
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corresponds to decreased protein levels (Figure 17). Also, bioinformatics analysis of 
the 3’UTR (Pique et al., 2008) show the presence of CPE sequences in all of these 
genes (Figure 17). 
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Figure 17: 3’ UTR, western blot and qRT-PCR analysis of neurodegeneration annotated genes with 
poly(A) tail altered in R6/1. 3’UTR of Mapt, Gsk3β and Snca mouse genes (upper panels). # Gsk3β 
3’UTR is only showed the 5’ extreme. [C] = Canonical CPE, [nC] = Non-Canonical CPE, (P) = Pumilio 
binding element, {H} = Hexanucleotide. In lower panels, levels Mapt (TAU), GSK3β and Snca (α-SYN) 
protein and its mRNA levels in St of R6/1 mice (n=7 for WT and R6/1 mice). 
Conclusion: St of R6/1 mice shows alteration of polyadenylation and protein levels of 
multiple neurodegeneration causing genes. These results therefore strongly support 
a causative role of CPEB dysfunction and global poly(A) tail length-alteration in HD 
and possibly also other neurodegenerative diseases and provide an explanation for 
the altered protein levels of multiple AD- and PD-related genes previously reported in 
HD in the absence of matching changes in their transcript levels. 
2.3. Study of the striatal atrophy associated gene Kinectin 1 in HD brain
After seeing that altered polyadenylation in R6/1 prominently affects genes 
previously known to participate in the etiology of neurodegenerative diseases, 
we performed data mining in search of genes not previously annotated as 
neurodegeneration-causing and that might contribute to basal ganglia dysfunction or 
atrophy. Kinectin 1 (Ktn1) is one of the genes showing remarkable poly(A) tail shortening 
in R6/1 mice (Figure 14B). Interestingly, in a recent genome-wide association study 
of common variants that affect volume of subcortical regions, the strongest effect 
was found for the putamen in a locus that affects expression of KTN1 and a direct 
correlation is found between KTN1 expression in frontal cortex and striatal volume 
(Hibar et al., 2015b). As expected, bioinformatics analysis of the 3’UTR of both mouse 
and human KTN1 genes revealed the presence of CPE sequences in both species and 
hKTN1 is detected by the algorithm that predicts functional CPEs (Pique et al., 2008). 
We then found by western blot decreased KTN1 protein levels both in Cx and St of 
R6/1 mice and HD patients (Figure 18). 
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This HD-associated decrease is also evident by immunohistochemistry in both 
species and in both structures (Figure 19). 
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Figure 18: 3’ UTR and western blot analysis of KTN1 in HD patients and R6/1 mice. KTN1 3’UTR of 
(A) mouse and (B) human genes. In lower panels, western blot analysis of mouse and human KTN1 
protein levels in Cx (upper panels, n=7 for WT and n=6 for R6/1 mice and n=4 for controls and HD 
patients) and in St (lower panels, n=7 for WT and R6/1 mice and n=8 for controls and n=5 for HD 
patients). [C] = Canonical CPE, [nC] = Non-Canonical CPE, {H} = Hexanucleotide. Data are as mean 
±SEM. * p < 0.05, ** p < 0.01, *** p < 0.001.
Conclusion: KTN1 is striatal atrophy associated gene that shows poly(A) shorting in 
R6/1 mice and presents functional CPEs. Protein levels of KTN1 are decreased in Cx and 
St of both, R6/1 mice and HD patients. These findings suggest that CPEB dependent 
alteration of polyadenylation may contribute to the prominent striatal atrophy of HD 
brains through inducing decreased protein levels of KTN1.
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Figure 19: KTN1 pattern in HD patients and mice Cx and St. (A) KTN1 expression determined by 
immunohistochemistry in sagittal sections of WT and R6/1 mice Cx (upper panels) and St (lower 
panels). CPu = Caudate Putamen, GP = Globus Pallidus. (B) Immunohistochemistry of KTN1 
expression in sections of formalin-fixed paraffin-embedded of human controls and HD patients Cx 
(upper panels) and St (lower panels).
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3. DETERMINE THE RELATIVE CONTRIBUTION OF CPEB1 AND CPEB4 TO POLY(A) 
CHANGES IN HD AND FIND CPEB DEPENDENT PATHWAYS AND GENE MODULES
3.1. CPEB1 and CPEB4 RNA immunoprecipitation and microarray analysis in St 
of WT and R6/1 mice
To determine the relative contribution of CPEB1 and CPEB4 to the mentioned 
poly(A) tail length changes or to find new pathways or modules CPEBs dependent, 
we performed RNA immunoprecipitation (RIP) followed by microarray analysis with 
striatal RNA from WT and R6/1 mice (Figure 20).
WT ↑CPEB1/↓CPEB4
HD mouse model
RNA / Protein crosslinking
Microarray analysis/mRNA identification
CPEB1 Ab CPEB4 Ab IgG
RNA Isolation
Immunoprecipitation
Extraction/Homogenization
Mouse St
RNA-Immunoprecipitation
Figure 20: RNA-immunoprecipitation and microarray analysis. Schematic view of the RIP 
procedures on St RNA from WT and HD mice.
This genome wide identification revealed that, regardless of genotype, 7.9% of 
transcripts were bound only by CPEB4, 5.8% only by CPEB1 and 7.0% by both 
(Figure 21A). When we compared the CPEB-specific targets with the changes in 
polyadenylation linked to HD, the only observed biased distribution was for CPEB4-
specific mRNAs, as these were enriched within the transcripts with shortened poly(A) 
tail (Figure 21B). 
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Interestingly, the largest fold change (f.c.) corresponded to the mRNA of Auts2 (Figure 
22A), a gene linked to ASD (Liu et al., 2015; Sultana et al., 2002). We then realized 
that transcripts from other high confidence ASD genes, like Dyrk1a, Cul3, and Ptchd1 
(Cat.1-2 in SFARI https://gene.sfari.org/autdb/GS_Home.do) were among the top forty 
CPEB4-targets with most prominent poly(A) shortening (f.c. ≤ -3.0). This enrichment 
of ASD risk genes is highly significant (29.7 fold enrichment, p= 2e-04; (Figure 22B). 
Figure 21: Comparison of CPEB1 and/or CPEB4 binders with transcripts with poly(A) tail changes 
in HD mice. (A) Number and percentage of CPEB1 and/or CPEB4 binders in St of WT and HD mice 
according to RIP experiment. (B) Percentage of CPEB1 only or CPEB4 only binders with shortened 
(red), lengthened (blue) and unaltered (purple) poly(A) tail in HD mice.
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5 -3.9 Slk STE20-like kinase
6 -3.9 Kpnb1 Karyopherin (importin) beta 1
7 -3.9 Ssr3 Signal sequence receptor, gamma
8 -3.8 Rp2h Retinitis pigmentosa 2 homolog (human)
9 -3.8 Bach2 BTB and CNC homology 2
10 -3.7 Cpsf6 Cleavage and polyadenylation specif ic factor 6
11 -3.7 Pan3 PAN3 polyA specif ic ribonuclease subunit homolog
12 -3.6 Tmx3 Thioredoxin-related transmembrane protein 3
13 -3.6 Ube2d3 Ubiquitin-conjugating enzyme E2D 3
14 -3.6 Epha3 Eph receptor A3
15 -3.6 Zfx Zinc f inger protein X-linked
16 -3.5 Crbn Cereblon
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20 -3.4 Mynn Myoneurin
21 -3.3 Cers6 Ceramide synthase 6
22 -3.2 Klhl28 Kelch-like 28
23 -3.2 Plagl1 Pleiomorphic adenoma gene-like 1
24 -3.2 Dtw d2 DTW domain containing 2
25 -3.2 9630041G16Rik RIKEN cDNA 9630041G16 gene
26 -3.2 Arl6ip6 ADP-ribosylation factor-like 6 interacting protein 6
27 -3.2 Ccdc88a Coiled coil domain containing 88A
28 -3.2 Sp3 Trans-acting transcription factor 3
29 -3.2 Ctso Cathepsin O
30 -3.2 Cul3 Cullin 3
31 -3.2 2810474O19Rik RIKEN cDNA 2810474O19 gene
32 -3.1 Tmco5 Transmembrane and coiled-coil domains 5
33 -3.1 Camk4 Calcium/calmodulin-dependent protein kinase IV
34 -3.1 Zhx1 Zinc f ingers and homeoboxes 1
35 -3.1 Cep290 Centrosomal protein 290
36 -3.0 Eif4a2 Eukaryotic translation initiation factor 4A2
37 -3.0 Wnt5a Wingless-related MMTV integration site 5A
38 -3.0 Metap2 Methionine aminopeptidase 2
39 -3.0 Ptchd1 Patched domain containing 1
40 -3.0 Birc6 Baculoviral IAP repeat-containing 6
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Figure 22: CPEB4 binders with the most shortened poly(A) tail. (A) Fold change (f.c), symbol and 
gene name and (B) Fold enrichment of high confidence ASD genes (SFARI Cat. 1-3 and Cat. 1-2) in 
CPEB4 binders in WT St whose poly(A) tail is shortened in an HD mouse model (f.c. ≤ -3.0). P-fisher 
value above bars. *** p<0.001.
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 Conclusion: Genes with shortened poly(A) tail in R6/1 mice show enrichment of 
CPEB4 binders. These CPEB4 targets with poly(A) shortening show a high enrichment 
of ASD risk genes. This serendipitous finding led us to hypothesize a role of CPEB4 in 
ASD gene expression. 
3.2. Enrichment analysis of CPEB binders in functional co-expression modules 
and ASD risk genes
To further explore the potential of CPEB4 as a key mediator of gene expression 
reprogramming associated with ASD pathogenesis, we analyzed the incidence of 
CPEB4 binders in a compiled set of 155 ASD genetic risk candidates from the SFARI 
database (ASD SFARI). CPEB4 binders are highly enriched (odds ratio [OR]=2.7, p=2e-
06) and also in a smaller curated list of ASD only genes (OR=2.6, p=6e-05) which cause 
ASD, but not intellectual disability (Figure 23A). CPEB1 target mRNAs were enriched 
to a lesser and less significant extent than CPEB4 binders, probably reflecting the 
common CPEB1/CPEB4 target mRNAs. 
We then performed enrichment analysis of the CPEB4 targets within the functional 
co-expression modules that represent shared pathology in ASD brain as identified in 
previous gene array (Voineagu et al., 2011) and RNA-seq studies (Parikshak et al., 
2016). CPEB4 binders are overrepresented in the array-identified ASD-associated 
modules, ASD.M16-array (OR=1.9, p=1e-05) and ASD.M12-array (OR=1.4, p=2e-02) 
that correspond to genes involved in neuroinflammation and synaptic processes 
respectively. Further in the RNA-seq identified modules, CPEB4 binders are enriched 
the most in the ASD.M12-RNAseq (OR=2.7, p=8e-08) and also in ASD.M16-RNAseq 
(OR=1.5, p=7e-03) and ASD.M4-RNAseq (OR=1.7, p=8e-04) which are involved in 
synapse and synaptic processes and downregulated in ASD samples (Figure 23B). 
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Figure 23: Enrichment of CPEB4 and CPEB1 binders (A) in ASD risk genes (ASD SFARI) and hand 
curated, excluding intellectual disability genes (ASD only), (B) in co-expression network modules 
involved in ASD (ASDM12, M4 & M16 RNAseq and asdM12 & M16 array).
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Next, we analyzed the incidence of functional CPE elements (http://genome.
crg.es/CPE/; 93% experimental validation accuracy) in the 3’ UTRs of mRNAs of ASD 
genes, specifically the genes in the highest confidence categories (Cat. 1-3) of the 
SFARI database and the 39 genes harboring rare de novo protein disrupting mutations 
(ASD39 list) identified in the two most largest whole exome sequencing studies in 
simplex ASD (De Rubeis et al., 2014; Iossifov et al., 2014). 68.8% of the genes in the 
two most confident categories SFARI Cat.1-2 and 79.5% of the ASD39 genes contained 
functional CPEs versus only 35.8% in the whole genome and 39.2% in the genes with 
elevated expression in brain (Figure 24A). These percentages were even higher if non-
consensus (TTTTACT, TTTTAAAT or TTTTCAT), but experimentally validated, CPEs were 
included in the algorithm with up to 100 % potential targets in the ASD39 list. 
Most of these CPE-containing ASD mRNAs correspond to CPEB4 targets, as 
we found a highly significant enrichment in CPEB4-bound mRNAs among the high 
confidence ASD gene. Thus, CPEB4 binders represented 50.9% of the genes SFARI 
(Cat.1-2), 53.3% in the most validated SFARI category (Cat.1) and 65.8% in the ASD39 
list, versus 15.1% in the brain transcriptome and 24.2% in the genes overexpressed in 
brain (Figure 24B). 
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Figure 24: Incidence of functional CPEs and CPEB4 binders in ASD risk genes. (A) Percentage 
of human transcripts with functional CPEs in their 3’UTR and (B) percentage of CPEB4-binding 
transcripts according to RIP experiment in: whole transcriptome (total), genes with increased 
protein levels in brain and high confidence ASD genes (SFARI Cat. 1-3 and ASD39 list). Number of 
genes in each category under bars, and p-fisher value above bars. * p<0.05, **p<0.01, *** p<0.001.
Conclusion: CPEB4 binding transcripts are enriched within both risk-genes and gene-
modules involved in ASD. Indeed, the majority of high confidence ASD genes harbor 
functional CPEs in their 3’ UTR. Altogether, these data suggest that a large number 
of mRNAs encoding factors associated with ASD are regulated by CPEB4-mediated 
polyadenylation.
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4. STUDY THE POSSIBLE ALTERATION OF CPEB4 IN IDIOPATHIC ASD BRAIN AND 
ITS POTENTIAL PATHOLOGICAL IMPLICATION
4.1. Analysis of CPEB4 protein, mRNA levels and splicing alterations in human 
idiopathic ASD brain
We then decided to explore whether CPEB4 is altered in brains of idiopathic ASD 
patients and, given the general cross-regulation of CPEBs, we analyze also the rest of 
CPEBs both at the transcript and protein levels. When we analyzed the RNA-seq data 
from samples of BA9 postmortem prefrontal cortex (Cx) of 43 idiopathic ASD patients 
and 63 neurotypical control subjects (Parikshak et al., 2016), we found unaltered 
transcript levels for CPEB1 and CPEB2, a slight decrease in CPEB3 transcript levels 
(p=0.02) and a slight increase in CPEB4 transcript levels in ASD (p=0.035, Figure 25). 
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Figure 25: qRT-PCR analysis of CPEBs in patients with ASD. CPEBs mRNA levels in idiopathic human 
ASD Cx samples according to RNA-seq data (Parikshak et al., 2016). n=43 for control, n=63 for ASD. 
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Interestingly, western blot analysis revealed that only CPEB4 protein levels are 
altered in BA8/9 Cx of idiopathic ASD cases (Figures 26). More precisely, CPEB4 protein 
levels are decreased despite increased transcript levels thus indicating prominent 
posttranscriptional regulation in line with the multiple CPE sequences in its mRNA 
3’UTR and the reported CPEB1- and CPEB4-mediated forward amplification loop 
(Calderone et al., 2016; Igea and Mendez, 2010). Interestingly, since CPEB4 levels in 
control subjects are high in early life and then decline, the decreased levels in ASD 
cases under 40 years (83.5% reduction, p=0.016) get even more significant if only the 
youngest cases are considered (Figure 26).
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Splicing alterations (Voineagu et al., 2011; Xiong et al., 2015) particularly of 
microexons (Irimia et al., 2014) have been reported in ASD. We thus analyzed RNA-
seq data from control (n=81) and ASD (n=82) subjects (Parikshak et al., 2016) for 
potential splicing alterations in mRNAs of the different CPEBs. 
Only CPEB4 showed splicing alteration in ASD samples. Interestingly, we found 
highly significant skipping of the 24-nt neuronal-specific microexon (exon 4) in the 
mutually exclusive event with exon 3 (8.2%, p=0.004) thus favoring the formation of 
the CPEB4Δ4 mRNA isoform (Figure 27A-B). We also found highly significant inclusion 
of exon 3 in the CPEB4Δ3 vs. full length (FL-CPEB4) skipped exon event (8.5%, p=0.003) 
which, together with an almost significant exclusion of exon 4 in the FL-CPEB4 vs. 
CPEB4Δ4 skipped exon event (6.3%, p=0.077), further contribute to increase the 
proportion of CPEB4Δ4 isoform (Figure 27B).
Since the microexon encodes the 8-aminoacid B variable region (Theis et al., 
2003), the favored CPEB4Δ4 isoform lacks multiple motifs for posttranslational 
modifications such as phosphorylation by AKT, S6K, PKA or PKC (NETPHOS 2.0  and 
Theis et al., 2003) (Figure 27A). This is suggestive of a dominant negative (DN) effect 
of CPEB4Δ4 -not only over CPEB4 but possibly over other CPEBs- by sequestering 
CPE-regulated mRNAs in line with what has been observed for non-phosphorylatable 
CPEB4 mutants regarding other residues (Guillen-Boixet et al., 2016). This DN effect 
would explain the observed disruption of the CPEB4 translational autoamplification 
loop. 
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Figure 26: Western blot analysis of CPEB4 in Cx (BA9) of idiopathic ASD patients; stratified by age 
and n indicated in histogram. Data are shown as mean ± SEM. * p < 0.05, ** p < 0.01.
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We then performed absolute qRT-PCR analysis to check whether the observed 
altered splicing events do in fact result in a net increase in the CPEB4Δ4 isoform 
and to interrogate the relative proportion of each of the four possible isoforms due 
to alternative splicing of exon 3 and exon 4 (full-length, CPEB4Δ3, CPEB4Δ4 and 
CPEB4Δ3Δ4) (Figure 28A). The most abundant mRNA isoform in control subjects is 
FL-CPEB4 (56%) followed by CPEB4Δ4 (21%). As anticipated by the splicing analysis by 
RNAseq, ASD subjects showed a significant increase of the CPEB4Δ4 isoform at the 
expense of the FL-CPEB4 isoform (Figure 28B). This way, the 56:21 FL-CPEB4:CPEB4Δ4 
ratio in controls becomes 46:31 in ASD subjects (Figure 28C).
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Figure 27: Analysis of CPEB4 splicing isoforms in ASD brains by RNA-seq data. (A) Schematic view 
of alternatively spliced exons (3-blue and 4-purple) of human CPEB4 mRNA. Inclusion of neural 
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Conclusion: Idiopathic ASD brains show: reduced CPEB4 protein levels and CPEB4 
mis-splicing, in particular an aberrant skipping of a neuronal-specific microexon that 
generates a CPEB4 variant potentially refractive to regulation. All of these results 
confirm the alteration of CPEB4 in ASD patients. 
4.2. Genome-wide poly(A) tail changes and concomitant protein 
alteration in idiopathic ASD brains
To test if the observed alteration of CPEB4 has an impact on mRNA polyadenylation 
in brains of idiopathic ASD cases, we explored potential genome-wide changes in 
mRNA poly(A) tail length and in particular of the ASD genes. For this, we performed 
poly(U)-chromatography on RNA purified from postmortem BA8/9 Cx tissue of control 
subjects (n=5; 5-21 years-old) and idiopathic ASD patients (n=6, 7-23 years old). 
Differential elution with 25% and 90% formamide yields two fractions of mRNAs with, 
respectively, short and long poly(A) tails, which were then analyzed by microarray 
hybridization (Figure 29). 
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Figure 29: Poly(U) chromatography and microarray analysis. (A) Schematic view of the poly(U) 
chromatography/microarray analysis experiment on RNA samples of Cx (BA8/9) from control (n=5) 
and ASD cases (n=6).
We observed that 10.2% of transcripts show poly(A) tail lengthening in ASD 
while 9.1% transcripts show poly(A) tail shortening (Figure 30). However, when ASD 
causing genes were specifically analyzed, we observed that deadenylation was the 
most salient feature. Remarkably, the highly significant poly(A) tail-shortening of ASD 
genes was progressively exacerbated with increased causality-confidence in the SFARI 
category gene modules (Figure 30). Thus, genes with shortened poly(A) reached 
19.1% in SFARI Cat.3, 26.3% in SFARI Cat.2, and 50% in SFARI Cat.1 (p= 1e-03, 6e-03 
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and 7e-04 respectively). Likewise, the incidence of transcripts with increased poly(A) 
tail length decreases along increasing causality confidence (6.2% in SFARI Cat.3, 2.6% 
in SFARI Cat.2, and 0% in SFARI Cat.1) (Figure 30). 
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Figure 30: Analysis of genes with poly(A) changes in ASD brains. Percentage of genes with 
shortened (red), lengthened (blue) or unaltered (purple) poly(A) tail length in ASD, in the whole 
transcriptome and in high confidence ASD genes (SFARI Cat.4 to Cat.1). P-fisher enrichment value 
of percentage of transcripts with poly(A) shortened in each SFARI Cat. above bars. ** p<0.01. *** 
p<0.001.
As expected, the CPEB4 binders are highly affected by this poly(A) tail shortening. 
In SFARI Cat.1-3 genes, CPEB4 binders represent 59% of the genes with shortened 
poly(A) (p = 0.026) versus 28.5% of the lengthened ones and 29.3% of the unchanged 
(Figure 31), thus supporting that deadenylation in ASD genes is due to CPEB4. 
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Figure 31: CPEB4 binders in ASD causing genes. Percentage of CPEB4 binders in ASD causing genes 
(SFARI Cat.1-3) for each poly(A) subgroup (shortened, lengthened and unaltered) in idiopathic ASD 
brains.
Finally, to determine the consequences of the ASD-associated poly(A) tail 
shortening on protein expression, we performed western blot analysis in BA8/9 
Cx tissue of controls and idiopathic ASD cases. The two CPEB4 target mRNAs with 
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most significant poly(A) shortening in SFARI Cat.1, namely PTEN and DYRK1A, show 
significantly decreased protein levels in ASD cases (Figure 32A), despite showing 
similar or even higher transcript levels (Figure 32B). Similarly, proteins encoded by 
SFARI Cat.2-3 genes with CPEB4-binding mRNAs that got deadenylated in ASD, show 
a similar significant decrease (RBFOX1) or a trend towards decreased levels (FOXP1, 
WAC, AUTS2) without any parallel alterations in transcript levels (Figures 32A-B). 
PCHD9, an SFARI Cat.4 gene whose transcript is bound by CPEB4 and shows one of 
the most prominent shortenings in poly(A) tail-length, also shows decreased protein 
levels despite significant increase in its transcript levels (Figures 32A-B).
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Figure 32: Protein and mRNA levels of ASD causing genes in ASD brains. (A) Protein and (B) mRNA 
expression levels of selected ASD genes whose poly(A) tail is shortened in idiopathic ASD samples 
(n=6) vs. control (n=5). Data are shown as mean ± SEM. n.s. non-significant, * p<0.05, ** p<0.01.
Conclusion: Idiopathic ASD brains show transcript-deadenylation of highly confidence 
ASD causing genes due to CPEB4 with concomitant decreased protein levels without 
changes in mRNA levels.
This led us to propose the decreased of levels of proteins encoded by deadenylated 
CPEB4 target mRNA as a new molecular signature in idiopathic ASD brains.
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5. GENERATION OF DIFFERENT MOUSE MODELS THAT MIMIC THE CPEB4 
ALTERATIONS FOUND IN IDIOPATHIC ASD FOR SUBSEQUENT POLY(A) 
ANALYSIS
5.1. Mouse models with modified CPEB4 expression
To further determine if CPEB4 alterations play a causal role in polyadenylation 
and translation of mRNAs of ASD genes, we generated different mouse models to 
mimic the specific changes observed in brains of idiopathic ASD patients. 
To mimic the decrease in CPEB4 protein level we used two models of CPEB4-
deficiency (Figures 33A-B). First, one with heterozygous gene trap (GT) between exons 
1 and 2 (CPEB4 GT/+ mice), showing partial reduction of CPEB4 protein (Figure 33A) 
without alteration in the ratio of the four alternative splicing-generated transcript 
isoforms (data not shown). This model expresses truncated CPEB4 (Figure 33A), more 
precisely the exon 1-encoded low complexity domain (LCD) (Hu et al., 2014; Shin 
et al., 2016). Second, a homozygous gene targeted deletion of constitutive exon 2 
(Calderone et al., 2016; Shin et al., 2016; Tsai et al., 2013) that results in a premature 
stop codon (CPEB4 KO mice) and shows full suppression of CPEB4 protein (Figure 
33B). 
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Figure 33: CPEB4 in GT and KO mice. (A) Schematic view of CPEB4 GT mice construct and Western 
blot analysis of CPEB4 protein levels (n=7). The gene trap (GT) cassette contains splice acceptor (SA), 
LacZ-neo (β-neo) and polyadenylation sequence (pA); low complexity domain (LCD) isoform. (B) 
Schematic view of CPEB4Δ2 mice (CPEB4 KO) construct and Western blot analysis of CPEB4 protein 
levels (n=2). Gene targeted deletion of the constitutive 82-nt exon 2 that results in a premature 
termination codon (PTC). Data are shown as mean ± SEM. ** p<0.01.
We next sought to explore the effect of a change in the CPEB4Δ4/FL-CPEB4 ratio, 
as observed in idiopathic ASD brains but without decreased CPEB4 global levels. For 
this aim, we generated mice with conditional neuronal-specific overexpression of 
CPEB4Δ4 isoform (TgCPEB4Δ4 mice, Figure 34A). No perinatal lethality was observed 
as the percentage of born TgCPEB4Δ4 mice matched the one expected with mendelian 
distribution (Figure 34B).
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Figure 34: Generation of TgCPEB4Δ4 mice. (A) Schematic view of TgCPEB4Δ4 mice construct: tTA 
(a.k.a. Tet-Off) is under control of the CamKII promoter and activates the BiTetO construct with 
NLS-β-Gal sequence in one direction and human CPEB4Δ4 in the other. (B) Breeding protocol to 
obtain TgCPEB4Δ4 mice. Number of mice, percentage of births observed and expected for the four 
experimental genotypes are shown in the table.
TgCPEB4Δ4 mice were indistinguishable from their WT and single transgenic 
littermates from birth to weaning. However, at this age (3 weeks), up to 40% of 
TgCPEB4Δ4 mice start showing cranial dysmorphology and hydrocephalus. TgCPEB4Δ4 
mice with cranial dysmorphology die prematurely with a mortality peak at the age of 
7 weeks (Figure 35A). The 60% of TgCPEB4Δ4 mice with normal cranial morphology 
do not develop hydrocephalus, do not present any obvious abnormality and do not 
show premature death (at least up to the oldest tested age of 20 months), but they 
are significantly smaller that their control littermates from the age of 3 weeks on 
(Figure 35B). For further characterization of TgCPEB4Δ4 mice in the rest of this study, 
we decided to restrict the analysis to the mice with normal cranial morphology.
B
Body Weight
0
5
10
15
20
2 3 4 5 6
B
od
y 
W
ei
gh
t (
gr
am
s)
Weeks
Control 
TgCPEB4∆4
Males
Control
TgCPEB4∆4
Females
25
***
***
***
*
^^^
^^^ ^^^
^^^
A
Control
TgCPEB4∆4
Probability of cranial
dysmorphology
Control
TgCPEB4∆4
Probability of survival
0
0.2
0.4
0.6
0.8
1
0 25 50 75 100 125P
ro
ba
bl
ity
 c
ra
ni
al
 d
ys
m
or
ph
ol
og
y/
su
rv
iv
al
 
Days
Transgene expression in TgCPEB4Δ4 mice takes place in neurons of forebrain 
structures such as Cx, St and Hipp. We can observe both overexpression of β-Gal 
reported (Figure 36A) and CPEB4∆4 protein in mouse forebrain (Figures 36B).
Figure 35: Life Span, cranial dysmorphology and body weight in TgCPEB4Δ4. (A) Kaplan-Meier 
curve for cumulative survival (continuous line) and probability of developing cranial dysmorphology 
(dashed line). n=44 for control, n=39 for TgCPEB4Δ4 mice. (B) Control and TgCPEB4Δ4 mice body 
weight (grams) evolution. Males (continuous line): n=25 control, n=9 TgCPEB4Δ4 mice. Females 
(dashed line): n=26 control, n=7 TgCPEB4Δ4 mice. Data are shown as mean ± SEM. * p<0.05. 
***p<0.001.
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Absolute qRT-PCR analysis revealed an imbalance of the alternative splicing-
generated isoforms (Figure 37A) similar to that observed in brain of idiopathic ASD 
patients (Figure 28A). Interestingly, total CPEB4 protein level in TgCPEB4Δ4 mice are 
highly increased at late embryonic age but only moderately increased in young adult 
(1.5 months) and no longer increased after 12-months despite significantly increased 
transcript levels at all age (Figure 37B). 
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Figure 36: β-Gal and CPEB4 expression in TgCPEB4Δ4 forebrain. (A) Immunohistochemistry 
showing β-Gal staining in neuronal nuclei in forebrain of a 1.5-month-old control and TgCPEB4Δ4 
mice. Cx: cortex. St: striatum. Hipp: hippocampus. LV: lateral ventricle. Scale bars represent 250 μm. 
(B) St CPEB4 immunohistochemistry shows cytoplasm pattern in control, overexpressing neurons in 
TgCPEB4Δ4 mice and no staining in CPEB4 KO. Scale bars represent 50 μm.
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Figure 37: CPEB4 splicing isoforms, mRNA and protein levels in TgCPEB4Δ4. (A) Percentage of each 
Cpeb4 splicing isoform with respect to total Cpeb4 mRNA, obtained by absolute qRT-PCR in St of 
controls (n=9) and TgCPEB4Δ4 mice (n=7), 1.5-month-old. (B) Western blot (upper panels) and qRT-
PCR (lower panels) analysis of CPEB4 in control and TgCPEB4Δ4 mice at embryonic day 18 (n=3), 
1.5-month-old (n=7) and 12-month-old (n=4).
Interestingly, the level of CPEB4 protein does not seem to be different in 
TgCPEB4Δ4 mice with or without hydrocephalus (Figure 38A) and no changes in 
transcript or protein levels of the other CPEBs were observed in TgCPEB4Δ4 mice 
(Figure 38B-C).
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Conclusion: We generated mouse models that mimic either CPEB4 deficiency (CPEB4 
GT and KO mice) and CPEB4 mis-splicing in favor of the isoform lacking a neuronal-
specific microexon (TgCPEB4Δ4 mice), that we observe in idiopathic ASD patients.
5.2. Genome wide poly(A) tail analysis in brains of mouse models with 
modified CPEB4 expression
RNAs from mice with partial or complete ablation of CPEB4, were subjected 
to poly(U)-chromatography followed by microarray analysis (Figures 39A-B). Both 
models showed similar changes in ASD genes polyadenylation but these were 
opposite to what we observed in ASD patients (Figure 30), i.e. CPEB4 deficient mice 
show prominent poly(A) lengthening in genes of SFARI Cat.3, .2, or .1 (Figures 39A-B). 
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Figure 38: CPEBs mRNA and levels in TgCPEB4Δ4. (A) Western blot analysis of CPEB4 protein levels 
in TgCPEB4Δ4 mice (5-week-old) with or without hydrocephalus (n=6). (B) mRNA expression by qRT-
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Figure 39: Poly(A) changes in CPEB4 deficient mice. Percentage of poly(A) tail changes in (A) CPEB4 
GT/+ and (B) CPEB4 KO mice in Cx-St samples, in the total transcriptome and in high confidence 
ASD genes (SFARI Cat.4 to 1). Poly(A) shortening (red), lengthening (blue) and no change (purple). 
P-fisher enrichment value of percentage of transcripts with lengthened poly(A) in each SFARI 
category with respect to the total transcriptome above bars. ** p<0.01, *** p<0.001.
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Therefore, we concluded that the decreased polyadenylation of ASD related 
mRNAs in ASD brains is not a direct consequence of their reduced CPEB4 levels.
However, poly(U)-chromatography of TgCPEB4Δ4 mice revealed a pattern of poly(A) 
tail length changes in ASD genes (Figure 40) very similar to the one observed in 
idiopathic ASD patients (Figure 30) with predominant deadenylation that gets 
progressively exacerbated with the increasing causality confidence of the ASD gene 
category. Thus, 12.5% of the whole transcriptome shows poly(A) tail shortening in 
TgCPEB4Δ4 mice and this increases to 26% in SFARI Cat.3, 32% in SFARI Cat.2, and 47% 
in SFARI Cat.1 genes (p=7e-04, 1e-02 and 7e-03 respectively) (Figure 40). 
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Figure 40: Poly(A) changes in TgCPEB4Δ4. Percentage of poly(A) tail changes in Cx-St samples in 
the total transcriptome and in high confidence ASD genes. P-fisher enrichment value of percentage 
of transcripts with shortened poly(A) in each SFARI category above bars. ** p<0.01, *** p<0.001.
To further confirm the poly(A) tail alteration detected by poly(U) chromatography, 
deadenylation of Auts2 mRNA was also verified by poly(A) tail (PAT) and Hire (high 
resolution) -PAT analyses (Figures 41A-B). 
Figure 41: PAT and Hire-PAT assays of Auts2 in Control and TgCPEB4Δ4 mice. (A) PAT assay of Auts2 
in control and TgCPEB4Δ4 mice (n=2). RNaseH (+) lines show transcripts devoid of poly(A) tail (A0); 
RNaseH (-) lines show a smear that correlates with the different poly(A) tail length. (B) Hire-PAT 
assay and quantification of Auts2 poly(A) tail i (n=3). Data are shown as mean ± SEM. *p<0.05.
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Interestingly, poly(A) tail changes in ASD and TgCPEB4Δ4 mice are equivalent not 
only because both show poly(A) shortening for ASD genes. More important, global 
transcriptome poly(A) alteration is coincident in ASD patients and TgCPEB4Δ4 mice. 
This is evidenced by the highly significant overlap (p<7e-43) between the total of genes 
with shortened poly(A) tail, as well as between the total of genes with lengthened 
poly(A) tail in ASD patients and TgCPEB4Δ4 mice (p<6e-111) (Figure 42). 
Conclusion: CPEB4 deficiency mouse models show prominent poly(A) lengthening 
in ASD risk genes, opposite to ASD patients. However, TgCPEB4Δ4 mice show a 
poly(A) alteration coincident to that in human ASD cases, not only in ASD risk genes 
(predominant deadenylation), but also in global transcriptome. These data therefore 
demonstrate that imbalance in CPEB4 splicing isoforms in transgenic mice results in 
poly(A) tail length-changes equivalent to those in idiopathic ASD human cases.
5.3. Western blot analysis of deadenylated ASD risk genes in TgCPEB4Δ4 mice
To confirm that poly(A) tail changes in TgCPEB4Δ4 mice impact in alteration of 
protein levels, we performed Western blot analysis. As was the case for the ASD 
patients, poly(A) tail shortened in the TgCPEB4Δ4 mice correlated with reduced 
protein levels of ASD genes. Analysis of the SFARI Cat. 1-3 genes which generate 
CPEB4-binding transcripts revealed that the two genes with most shortened poly(A) 
tail, namely Zbtb20 and Tnrc6b, showed significant St and Cx reduction in protein 
levels, without concomitant transcript level changes (Figures 43A-B). Similarly, the 
third most deadenylated transcript (Pten) showed a tendency to decrease in Cx. We 
Figure 42: Comparison of genes with poly(A) changes ASD vs. TgCPEB4Δ4 mice. Percentage of 
genes with shortened (red), lengthened (blue) or unaltered (purple) poly(A) tail length in ASD 
Cx (BA8/9) samples and Cx-St in mice in the whole transcriptome is shown inside the columns. 
Representation factor (R.f.) and p-values of transcripts with poly(A) changes in same direction (left 
panel) and in opposite direction (right panel).
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also found significant St and Cx -decreases in protein levels for Chd2, Foxp1, Wac, 
Auts2, and Rbfox1 in TgCPEB4Δ4 mice. Interestingly, SFARI Cat.4 genes with robust 
poly(A) tail shortening such as Gpc6 also show decreased protein levels in the absence 
of transcript level changes (Figures 43A-B). 
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Figure 43: Protein and mRNA levels of ASD causing genes in ASD brains.  (A) Western blot analysis 
in Cx and St of ASD genes whose poly(A) tail is shortened in 1.5-month-old TgCPEB4Δ4 mice (n=7). 
(B) mRNA expression levels in Cx-St samples of the same ASD genes in control and TgCPEB4Δ4 mice 
(n=3). Data are shown as mean ± SEM.* p<0.05, ** p<0.01.
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Conclusion: Numerous deadenylated ASD genes show diminished protein levels in 
TgCPEB4Δ4 mice. These results demonstrate that in vivo selective alteration of the 
ratio of CPEB4 splicing isoforms in favor of CPEB4Δ4 is sufficient to alter the protein 
levels of numerous ASD risk genes.
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6. CHARACTERIZATION OF ASD PHENOTYPE IN TGCPEB4∆4 MICE
In view of the similar poly(A) tail- and protein level-alteration of multiple high 
confidence ASD genes in brains of idiopathic ASD patients and TgCPEB4Δ4 mice, we 
tested whether these mice developed ASD-related anatomical, electrophysiological 
and behavioral abnormalities. 
TgCPEB4Δ4 mice show reduced brain weight and volumetric analysis of forebrain 
regions revealed 27.1% volume reduction in Cx, 24% in St and 15.7% in hippocampus 
(Figures 44A-B). 
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Because dendritic spine dysgenesis is frequent in ASD (Phillips and Pozzo-Miller, 
2015) and mouse models (Chen et al., 2015), we analyzed this by rapid Golgi spine 
analysis. Similarly to other ASD models (Peca et al., 2011; Schmeisser et al., 2012), 
we found a 9.2% decrease in total spine density in TgCPEB4Δ4 mice (p=0.04) (Figure 
45) without changes in their relative distribution among filopodia, thin, stubby or 
mushroom spines (data not shown).
Figure 44: Brain weight and volume in TgCPEB4Δ4 mice. (A) Brain weight in control (n=24) vs. 
TgCPEB4Δ4 (n=7) mice. (B) Volumetric analysis of toluidine blue stained brain sections from control 
(n=10) and TgCPEB4Δ4 mice (n=5). Histogram shows percentage volume reduction of TgCPEB4Δ4 
forebrain structures (cortex, striatum and hippocampus). Data are shown as mean ± SEM. ** 
p<0.01, ***p<0.001.
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Figure 45: Spine morphology and density in TgCPEB4Δ4 mice. Confocal images of Golgi staining in 
Cortex. Histogram shows spine density (spines/μm) in layers II/III of pyramidal neurons (n=14 cells 
from 5 control and n=12 cells from 4 TgCPEB4Δ4 mice). Data are shown as mean ± SEM. * p<0.05.
Next we tested whether the decreased spine density in TgCPEB4Δ4 mice 
correlates with electrophysiological alterations, as observed in other ASD mouse 
models (Chen et al., 2015) like those with altered NLGN-neurexin function (Rabaneda 
et al., 2014). We thus performed whole-cell recordings of miniature excitatory 
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postsynaptic currents (mEPSCs) in layer V pyramidal neurons of somatosensory Cx. 
The analysis of the average mEPSCs in each cell reveals no difference in the mean 
amplitude, but the mean frequency was decreased in TgCPEB4Δ4 (7.41 ± 0.85 Hz) vs. 
control (10.95 ± 1.15 Hz) that is a 32% reduction (Figure 46). In line with the observed 
deficit in spine density, these observations are compatible with a presynaptic deficit 
in neurotransmitter release and/or a reduction in the number of excitatory synapses. 
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Figure 46: Electrophysiology characterization of TgCPEB4Δ4 mice. Representative traces and 
quantification of amplitude (pA) and frequency (Hz) of mEPSCs recorded from pyramidal neurons 
of the somatosensory Cx (n=11 cells from five control and n=9 cells from five TgCPEB4Δ4 mice). 
Data are shown as mean ± SEM.* p<0.05.
ASD diagnosis criteria in humans are based in behavioral symptoms rather than 
biochemical or neuroanatomical markers. To further validate TgCPEB4Δ4 mice as an 
ASD model, we performed a battery of ASD-related behavioral tests that included 
Open Field (OF), Ultrasonic Vocalization (UsV) and Social Approach (SAp) tests. 
In the OF, a test to characterize the general activity pattern, TgCPEB4Δ4 mice 
showed stereotypical running at the periphery of the cage while they showed no 
difference in the distance walked in the center (Figure 47A). This higher activity in the 
periphery of the arena could suggest anxiety-related behavior and we thus decided to 
perform the Elevated Plus-Maze (EPM) test to explore this possibility. However, since 
TgCPEB4Δ4 mice spent about the same amount of time in open and closed arms, they 
rather show reduced anxiety (Figure 47B). 
A
0
750
1500
2250
3000
Periphery Center
D
is
ta
nc
e 
(c
m
)
*
Close arms
Open arms
0
50
100
150
Control TgCPEB4∆4 
Ti
m
e 
(s
)
***
n.s.
Elevated Plus MazeOpen Field B
Control
Control
TgCPEB4∆4
TgCPEB4∆4
Figure 47: Evaluation of the open field and elevated plus maze tests in TgCPEB4Δ4 mice. (A) 
Representative traces of movement of control (n=51) and TgCPEB4Δ4 (n=13) mice in the open field 
test and quantification of distance travelled (cm) in the periphery and in the center. (B) Time spent 
in closed or open arms in the elevated plus maze of control (n=15) and TgCPEB4Δ4 (n=19) mice. 
Data are shown as mean ± SEM. n.s. non-significant, * p<0.05, *** p<0.001.
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The UsV test analyzes ASD-relevant infant-mother communication by measuring 
isolation-induced calls emitted by pups in the absence of their mother (Silverman et 
al., 2010). We analyzed the pattern of UsV emission during postnatal development 
(P3-6-9-12) and found that, from P6 on, TgCPEB4Δ4 mice emitted significantly less 
UsVs (Figure 48).
Figure 48: Analysis of ultrasonic vocalizations in TgCPEB4Δ4 pups. (A) Number of ultrasonic calls 
from pups during 5 min when separated from their mothers at postnatal day 3, 6, 9 and 12. Control 
(n=20) and TgCPEB4Δ4 (n=13) mice. Data are shown as mean ± SEM. ** p<0.01.
In order to analyze social behavior, we performed the SAp test, which measures 
sociability as a preference to interact with a cage containing a mouse rather than 
with an empty cage (Silverman et al., 2010). We found that while the controls spent 
significantly more time interacting with the mouse containing cage, indicative of 
normal sociability, TgCPEB4Δ4 mice did not show any significant preference to interact 
with either cage, indicating a dysfunction in sociability (Figure 49). 
Figure 49: Assessment of social interaction behaviors in TgCPEB4Δ4 mice. Time interacting with 
either an inanimate object (empty cage), an unfamiliar mouse or without any interaction during 10 
min. Control (n=20) and TgCPEB4Δ4 (n=7) mice. Data are shown as mean ± SEM. n.s non-significant, 
** p < 0.01, *** p < 0.001.
Conclusion: TgCPEB4Δ4 mice show ASD-like neuroanatomical, electrophysiological 
and behavioral phenotypes. Together, the neuroanatomic alteration, the stereotypic 
behavior, the aberrant infant-mother communication and the deficit in social 
interaction demonstrate that ASD-like altered CPEB4 isoform ratio in vivo results in 
core ASD-related phenotype.
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Huntington’s disease (HD) is a high prevalence neurodegenerative disorder 
characterized by motor disturbance, cognitive decline, behavioral, psychological 
dysfunction and premature death. Thus, scientists are making huge efforts to 
understand how the HTT mutation causes the characteristic HD phenotype and to 
find new treatments.
In this thesis we focused on studying the potential role of CPEBs in HD. CPEBs 
are a family of proteins that regulate translational-repression or –activation through, 
respectively, cytoplasmic shortening or elongation of the mRNA poly(A) tail. We 
reasoned that altered CPEB function might contribute to HD based on different lines 
of evidence. Thus, the first aim of this thesis was to explore the status of CPEBs in HD 
and the potential genome-wide poly(A) tail changes of target mRNAs. Strikingly, we 
noticed that high confidence ASD-causing genes were unexpectedly overrepresented 
among CPEB4 targets. This serendipitous finding led us to hypothesize CPEB4 as a 
new hub in ASD gene expression. Thereby, the second aim was to study the status of 
CPEB4 in idiopathic ASD patients and finally to determinate its potential role in ASD 
risk gene regulation. 
Altered mRNA polyadenylation and protein levels of neurodegeneration causing 
genes upon CPEB1/4 imbalance in Huntington’s disease
As the first analysis of the status of CPEBs in HD, here we find strong imbalance 
of CPEBs in human HD St and also in others affected brain structure such Cx, Hipp 
or Cb (data not show), characterized by increased levels of CPEB1 and a decrease in 
CPEB4. Transgenic HD mouse models show similar CPEB imbalance with subsequent 
altered poly(A) tail length for hundreds of mRNAs. These transcripts are enriched in 
gene modules previously associated with neurodegeneration, not only in HD but also 
in AD and PD thus suggesting that CPEB alteration may represent a new common 
pathogenic mechanism across neurodegenerative diseases. Besides, this analysis has 
allowed detection of altered mRNA polyadenylation and protein levels of KTN1 that 
may explain the prominent striatal atrophy that occurs in HD.
Regarding the mechanism by which CPEB alteration takes place in HD, it would 
be expected to be an age-associated phenomenon triggered by the toxicity of the 
expanded CAG-mRNA and/or polyQ. For instance, global transcriptomic changes 
induced by expanded polyQ are well known mechanisms in HD pathogenesis (Valor, 
2015) and the increase in CPEB1 protein could be explained by the observed increase 
in CPEB1 mRNA level. However, the decrease in CPEB4 protein level is not mirrored 
by a change in its mRNA level. Interestingly, we have evidence that calpain activation, 
86
VI. DISCUSSION
which is known to happen along HD pathogenesis (Gafni and Ellerby, 2002), results in 
increased CPEB4 proteolysis and degradation (data not shown).
Regarding if both the excess of CPEB1 or defect of CPEB4 contribute to HD 
pathogenesis, we decided to correct these CPEB alterations in HD mice. Thus, on 
one hand we generated HD mice with decreased levels of CPEB1 by combining R6/1 
and heterozygote CPEB1 KO (CPEB1 +/-) mice. On the other hand we generated HD 
mice with overexpression of CPEB4 by combining R6/1 and transgenic CPEB4∆4 mice. 
The average half-life of CPEB1+/- R6/1 double transgenic mice was even lower that 
of the R6/1 mice and we founded no improvement of HD-like phenotype (data not 
show). However, TgCPEB4∆4 R6/1 double transgenic mice showed slight attenuation 
of motor symptoms in rotarod and in open field tests without any change in life span 
(data not shown). These results suggest that decrease of CPEB4 protein levels in HD is 
more relevant for disease pathogenesis. We did not find strong attenuation of HD-like 
phenotype probably because we only restored the levels of CPEB4∆4 isoform in R6/1. 
Now, our effort is to generate a transgenic mouse with overexpression of the neural 
specific CPEB4 isoform, the full length CPEB4. Finally, we will study the HD phenotypic 
progression by crossing with HD mice. 
One of the most salient features in this thesis is the enrichment in genes of the 
HD-, AD- or PD-related modules among the genes with significant poly(A) tail length 
alteration in HD mice. This suggests that CPEB alteration in HD is pathogenic by aberrant 
polyadenylation of many neurodegeneration-associated genes. Two genes classically 
implicated in HD etiology, HTT itself and BDNF are among the genes displaying altered 
poly(A) tail length, increased for HTT and decreased for BDNF mRNA. mHTT toxicity is 
obviously mediated by its expanded polyQ tract and decreased BDNF protein levels can 
be explained by its well documented decreased transcription (Zuccato and Cattaneo, 
2009). However, our data suggest that CPEB mediated dysregulation may exacerbate 
both toxic entities by further increasing mHTT translation and further decreasing BDNF 
translation. In fact, there was previous evidence of CPEB mediated regulation of BDNF 
in non-pathological conditions (Baj et al., 2016; Ma et al., 2010; Oe and Yoneda, 2010; 
Vicario et al., 2015). Recently, our lab and others have demonstrated that two genes 
associated to AD, MAPT and GSK3β, are also implicated in HD (Fernandez-Nogales et 
al., 2014; Fernandez-Nogales et al., 2015; Vuono et al., 2015). Intriguingly, excess Tau 
and decreased GSK3β protein levels without matching altered transcript levels have 
been shown to contribute to HD-like phenotype in R6/1 mice (Fernandez-Nogales et 
al., 2014; Fernandez-Nogales et al., 2015). The here reported increased poly(A) tail 
length in MAPT and decreased poly(A) tail length in GSK3β provide an explanation for 
such pathogenic altered protein levels. 
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The high incidence of neurodegeneration causing genes among transcripts with 
poly(A) tail alteration in the mice with CPEB alteration also suggests that similar or even 
complementary CPEB alterations might underlie other neurodegenerative diseases. 
Now, we are analyzing levels and patterns of all CPEBs in brain structures affected in 
patients of other neurodegenerative diseases as PD or AD (data not shown).
Kinectin 1 is an integral endoplasmic reticulum (ER) membrane protein that 
anchors kinesin-1 to extend the ER along microtubules and that also anchors elongation 
factor-1 complex to facilitate translation in the ER (Ng et al., 2016; Ong et al., 2006). 
As mentioned, striatal volume has recently been reported to be proportional to KTN1 
gene expression in Cx (Hibar et al., 2015a). At least in mice, Ktn1 mRNA is much 
higher in Cx than in St (http://mouse.brain-map.org/). All this, together with the here 
showed decreased KTN1 protein levels both in cortical and striatal tissue and the 
predominant neuropil immunostaining of kinectin in St, suggest that striatal atrophy 
might be secondary to decreased microtubule dependent transport and protein 
synthesis in cortico-striatal afferences. 
Thus, it would be crucial to study in depth the status of CPEBs and global 
polyadenylation not only in HD, but also in other neurodegenerative diseases such AD 
and PD. We could think of a common pathogenic mechanism in all neurodegenerative 
diseases as CPEBs are very well positioned to trigger aberrant gene expression of 
multiple neurodegeneration-associated genes in patient’s brain. 
In summary, by showing CPEB1/CPEB4 imbalance in HD leading to poly(A) tail 
changes in numerous transcripts previously associated to neurodegeneration, not 
only in HD but also in AD and PD, our results suggest a common new CPEB-related 
pathogenic mechanism across neurodegenerative diseases. Altered polyadenylation of 
multiple transcripts therefore becomes a new molecular signature in HD and possibly 
other neurodegenerative diseases that will allow identification of new pathogenic 
effectors. In this regard, we here identify diminished KTN1 as a likely etiology player 
responsible for the prominent striatal atrophy in HD. 
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CPEB4 mis-splicing reprograms mRNA polyadenylation and gene expression in 
autism
Our study of CPEBs in HD serendipitously took us to discover a new molecular 
mechanism in the highly prevalent neurodevelopmental disorder ASD. 
We found an unexpected and very significant enrichment of ASD susceptibility 
genes among CPEB4 targets with shortened poly(A) tail in a mouse model of HD. 
Indeed, CPE sequences are present in 3’ UTRs of most high confidence ASD gene 
transcripts which in turn are overrepresented among the CPEB4-binding transcripts. 
Moreover, by analyzing postmortem brains of idiopathic ASD cases we found that 
CPEB4 shows diminished protein levels and it is mis-spliced in favor of the isoform 
lacking a neuronal-specific microexon. This led us to discover a new molecular 
signature in idiopathic ASD brains consisting on poly(A) tail length shortening in 9% 
of the transcriptome that prominently affects high confidence ASD risk genes (as an 
example, half of the SFARI Cat. 1 genes show decreased poly(A) tail length in idiopathic 
ASD brains). This is accompanied by concomitant decreased protein levels without 
mRNA levels alteration of deadenylated CPEB4-target ASD genes in autistic brains. 
The causal role of the CPEB4 alteration on these ASD gene poly(A) tail length- and 
protein level-changes is evidenced by the fact that equivalent imbalance in CPEB4 
splicing isoforms in transgenic mice results in similar poly(A) tail length-changes and 
in decreased protein levels of a plethora of ASD genes including AUTS2, CHD2, FOXP1, 
GPC6, RBFOX1, TNRC6B, WAC and ZBTB20. As expected, these mice show robust ASD-
like anatomical, electrophysiological and behavioral phenotypes. 
Unlike mutations responsible for monogenic syndromes with autistic features, 
such as Rett or Fragile X, most mutations associated with non-syndromic ASD have a 
limited impact per se (Gaugler et al., 2014). Therefore, the co-existence of multiple 
genetic factors together with perturbations of neurodevelopment able to impact 
expression of other ASD related genes are believed to contribute to non-syndromic 
and idiopathic ASD (Kim and Leventhal, 2015). A critical goal of in ASD research is to 
identify potentially convergent molecular pathways (Parikshak et al., 2013; Voineagu 
et al., 2011) as well as finding altered regulators able to simultaneously orchestrate 
expression of multiple ASD genes in concordance to neurodevelopment affecting 
cues. Interestingly, our study reveals that CPEB4 is excellently positioned to act as 
such a hub in ASD gene expression and to become a therapeutic target for a wide 
range of idiopathic and even syndromic ASD etiologies.
CPEB4 shows highest expression levels both in mouse embryo and in adult brain 
(Shin et al., 2016; Theis et al., 2003) and CPEBs modulate translation of specific 
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transcripts during gametogenesis and early development in response to extracellular 
stimuli such as progesterone and insulin (Sarkissian et al., 2004). Thus, it is conceivable 
that other development-modifying factors such as vitamins, nutrients, pollutants 
or mediators of inflammation that have been proposed as possible environmental 
factors accounting for the 50% of ASD causality that is not genetic (Hallmayer et al., 
2011; Sandin et al., 2014) could also impact CPEB4 developmental functions. This 
way, CPEB4 might modulate, as a consequence of development perturbations, the 
expression of many of the genes that have individually been proven to contribute to 
ASD pathogenesis. Besides, we have demonstrated that the pathogenic effect of CPEB4 
isoforms imbalance is exerted during mouse early development. More precisely, we 
observed that conditional TgCPEB4∆4 mice did not show any ASD-like phenotype if 
we prevent the exogenous CPEB4∆4 expression by treating dams during pregnancy 
with doxycycline (data not shown). However, they did not correct or attenuate ASD 
phenotype if the doxycycline treatment was given after weaning (data not shown). 
Thus, CPEB4 becomes a potential therapeutic target in pregnant mother that have 
been exposed to toxins or have suffered infection and/or immune activation. 
With this hub position of CPEB4 in ASD gene expression, the question emerges of 
why the powerful genomic analyses of large ASD cohorts did not identify mutations in 
CPEB4. We could list different possible explanations: It is estimated that ∼1000 genes 
are likely to be involved to ASD however only a few hundred are known, thus, probably 
CPEB4 had not been reported yet. CPEB4 deficient mice do not mimic the molecular 
signature observed in ASD patients nor show the ASD-like electrophysiological and 
behavioral alterations observed in TgCPEB4Δ4 mice (data not shown). Therefore, 
neither deletions harboring the CPEB4 gene, nor loss of function mutations or 
promoter polymorphisms leading to decreased expression of CPEB4 are expected to 
be ASD-causative. Other likely explanation is that the pathogenic CPEB4 alteration 
that leads to ASD is triggered by environmental factors that indirectly alter its splicing 
and function. In fact, we have preliminary evidence of altered CPEB4 splicing in the 
maternal immune activation model of ASD (data not shown). Furthermore, prenatal 
cytomegalovirus (CMV) infection has been related to ASD (Engman et al., 2015; 
Ornoy et al., 2015), and recent study has shown than CPEB1 was highly induced and 
also CPEB4, after CMV infection. This results in widespread alternative splicing (AS), 
shortening of 3′ UTRs and lengthening of poly(A) tails in host gene transcripts (Batra 
et al., 2016). 
Recently, we have generated mice with double CPEB4 modification (heterozygote 
KO of endogenous CPEB4 and CPEB4∆4 overexpression). These double TgCPEB44:CPEB4 
KO mice show imbalance of CPEB4∆4 isoform but do not show excess of total CPEB4. 
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As we expected, they show ASD-like anatomical and behavioral phenotype (data not 
shown), confirming that only the alteration of the ratio of CPEB4 splicing isoforms in 
favor of CPEB4Δ4 induces ASD phenotype. Thus, the only genetic variants that would 
mimic the pathogenic splicing alteration would be intronic mutations flanking the 
24-nt microexon or selective deletion of this single exon. Such mutations would most 
likely have gone unnoticed in most genetic screens as these normally detect exonic 
mutations (De Rubeis et al., 2014; Iossifov et al., 2014) and bigger CNV (Levy et al., 
2011). It is worth noting though that the SFARI collection of large CNV associated 
with ASD includes a duplication within the CPEB4-containing 5q35.1-q35.3 region 
(Kaminsky et al., 2011) .
Splicing alteration and particularly of microexons has previously been implicated 
in ASD pathogenesis (Irimia et al., 2014; Xiong et al., 2015). Interestingly, RBFOX1 
is one of the few splicing factors known to enable microexon processing (Li et al., 
2015) and it has recently been shown to regulate alternative splicing of CPEB4 in 
muscle (Pedrotti et al., 2015). Here we show that RBFOX1 transcript is a target of 
CPEB4 and that RBFOX1 protein levels are decreased in idiopathic ASD brains and in 
TgCPEB4Δ4 mice. This leads us to speculate on a potential feed forward loop. CPEB4 
alteration in ASD patients will lead to decreased RBFOX1 levels that would impact 
CPEB4 splicing further favoring the pathogenic mis-spliced isoform encoding a CPEB4 
isoform refractive to regulation by various kinases thus further dysregulating CPEB4 
activity, that in turn will further decrease RBFOX1 translation. 
We have demonstrated here that the ASD-CPEB4 splicing variant results in 
altered expression of multiple genes that had been previously linked to ASD with 
high confidence because they harbor mutations that co-segregate with disease. It is 
possible though that other poly(A)-altered genes in the less confidence categories or 
not in SFARI gene database at all may also significantly contribute to pathogenesis. 
Their protein levels may change selectively in neurons specifically at late embryonic 
or postnatal developmental stages, but that their mutations have not been found 
replicated in multiple studies or that they cannot harbor mutations themselves, for 
instance because these would be lethal when expressed in all cell types and/or during 
earlier developmental stages. Since our study unravels a new molecular signature, 
-poly(A) tail length shortening- associated to the change in gene expression, 
correlation analysis of the genes with altered poly(A) tail length with proteomics data 
and the genes in modules functionally involved in ASD may unravel new effectors in 
idiopathic ASD. 
We still do not fully understand the pathogenic mechanism by which imbalance 
of CPEB4∆4 caused ASD. Interestingly, CPEB4Δ4 lacks a microexon that may regulate 
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CPEB4 activity by phosphorylation (Theis et al., 2003; Wang and Cooper, 2010) and the 
decreased protein synthesis and polyadenylation of ASD-related genes in TgCPEB4Δ4 
mice and ASD brains together with decreased CPEB4 total protein levels suggest a 
dominan negative (DN) effect of CPEB4Δ4 isoform over CPEB4 and most likely also 
over the other CPEBs. This may explain why molecular and behavioral phenotypes of 
CPEB4 KO(GT)/+ mice and CPEB4 KO mice are opposite to those of TgCPEB4Δ4 mice. 
The different CPEBs bind in a competitive manner the same cis-acting element (CPE) 
and therefore can bind the same mRNAs (Afroz et al., 2014; Stepien et al., 2016). As 
an example, here we describe that 7.9% of transcripts were bound only by CPEB4, 
5.8% only by CPEB1 and 7.0% by both. Expression of a DN-CPEB4 will not change this 
distribution, but CPEB4-KO will free the CPEB4-enriched targets to become CPEB1 
targets. Thus KO of a CPEB causes a rearrangement in the regulation of CPE-mRNAs 
distinct from a CPEB-DN (as reviewed in (Fernandez-Miranda and Mendez, 2012) 
(Figure 50).
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Figure 50: Mouse and human data fit a dominant negative effect of CPEB4∆4 over CPEB4 and also 
over the other CPEBs. Schematic cartoon showing the dominant negative (DN) effect of CPEB4Δ4 
over CPEB4 and over other CPEBs (e.g. CPEB1) in three different scenarios (A) WT (B) TgCPEB4Δ4 
and (C) CPEB4 KO mice.
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Recent advances in splicing modulating therapies and the use of antisense 
oligonucleotides (AONs) to treat neurological disorders (Evers et al., 2015) might open 
new possibilities for CPEB4 as a therapeutical target for ASD. In this case, induction of 
exon inclusion, could be attempted for instance with AONs targeting putative splicing 
silencers affecting this microexon or by adding an oligonucleotide tail that recruits 
exon inclusion factors. In this case, RBFOX1 would be an excellent candidate for the 
above mentioned reasons. Another gene therapy strategy could be based on specific 
silencing of the transcripts lacking the microexon. 
In summary, we demonstrate that CPEB4, which was known to participate in 
development and in brain plasticity, is altered in ASD with a concomitant new molecular 
signature of decreased polyadenylation and altered translation of numerous high 
confidence ASD causing genes, thus providing a potential link between genetic and 
environmental factors in ASD. Collectively, these data unravel a key role of CPEB4 
in ASD and open new therapeutic opportunities for a wide range of idiopathic ASD 
etiologies.
Final remarks
By showing CPEB1/CPEB4 imbalance in Huntington’s disease leading to poly(A) 
tail changes in hundreds of transcripts previously associated to neurodegeneration 
not only in HD but also in AD and PD, our results suggest a common new CPEB-related 
pathogenic mechanism across neurodegenerative diseases. We also demonstrate 
that CPEB4, which was known to participate in development and in brain plasticity, 
is altered in ASD and plays a crucial role in translationally controlling expression of 
the majority of high confidence ASD causing genes, thus providing a potential link 
between genetic and environmental factors in ASD. Collectively, this thesis unravels a 
key role of CPEB4 in neurodegeneration and autism spectrum disease.
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1. BRAIN TISSUE SAMPLES
1.1. Patients Samples
Brain specimens used in immunoblot and IHC from frontal Cx and St of HD patients 
and controls (CTRL) were provided by Institute of Neuropathology Brain Bank (HUB-
ICO-IDIBELL, Hospitalet de Llobregat, Spain), the Neurological Tissue Bank of the 
IDIBAPS Biobank (Barcelona, Spain), the Banco de Tejidos Fundación Cien (BT-CIEN, 
Madrid, Spain) and the Netherlands Brain Bank (Amsterdam, The Netherlands). Brain 
specimens used in immunoblot, poly(U) chromatography and qRT-PCR from frontal 
cortex - BA8/9 of ASD patients and CTRL were provided by University of Maryland 
Brain and Tissue Bank, NIH NeuroBioBank (NBB) (Baltimore,MD) and the Autism 
Tissue Program (ATP) brain bank at The Harvard Brain and Tissue Bank (Blemont, MA). 
Written informed consent for brain removal after death for diagnostic and research 
purposes was obtained from brain donors and/or next of kin. Procedures, information 
and consent forms have been approved by the Bioethics Subcommittee of Consejo 
Superior de Investigaciones Científicas (CSIC, Madrid, Spain). RNA sequencing data 
from human brain tissue (ASD and CTRL individuals) were directly obtained from 
(Irimia et al., 2014) and (Parikshak et al., 2016).
1.2. Mouse Models
We used different previously reported mouse models: R6/1 transgenic mice for 
the human exon-1-Htt gene (Mangiarini et al., 1996) in B6CBAF1 background, HD94 
mice that express N-terminal Htt with an interrupted 94 CAG repeat (Yamamoto et al., 
2000) and heterozygous knock-in of an expanded CAG track in exon 1 of huntingtin 
gene, zQ175 mice (Menalled et al., 2012) both in C57BL/6J background, heterozygous 
CPEB4 gene trap (CPEB4 GT/+) and CPEB4 KO (Calderone et al., 2016). Conditional 
mice expressing human CPEB4 lacking exon 4 (TgCPEB4∆4) in C57BL/6 background 
were generated for this study (for details, see “Generation of TgCPEB4∆4 mice” 
below). All mice were housed at the Centro de Biología Molecular “Severo Ochoa” 
animal facility. Mice were housed four per cage with food and water available ad 
libitum and maintained in a temperature-controlled environment on a 12/12 h light-
dark cycle with light onset at 08:00. Animal housing and maintenance protocols 
followed the guidelines of Council of Europe Convention ETS123, recently revised as 
indicated in the Directive 86/609/EEC. Animal experiments were performed under 
protocols (P15/P16/P18/P22) approved by the Centro de Biología Molecular Severo 
Ochoa Institutional Animal Care and Utilization Committee (Comité de Ética de 
Experimentación Animal del CBM, CEEA-CBM), Madrid, Spain.
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2. EXPERIMENTAL TECHNIQUES
2.1. Genotype
Mouse genomic DNA was isolated from tail biopsies following digestion at 60°C 
in buffer containing 100 mM Tris-HCl (pH 7.8), 5 mM EDTA, 200 mM NaCl, 0.1% SDS 
and 1mg/ml proteinase K, followed by heat inactivation. After add NaCl 6M, samples 
were centrifuged at 13000 rpm for 10 min and supernatants were removed to new 
tube with 500 μl of isopropanol. Samples were centrifuged 13000 rpm for 10 min and 
pellets were washed with 300 μl of ethanol. Finally, DNA was resuspended in 100 μl 
of nuclease-free water.
PCR was performed according to the manufacturer’s instructions (Promega, 
GotTaq® G2 Flexi DNA polymerase, M7805) and with specific primer pairs:
2.2. Immunoblot
Samples from human brain were stored at -80°C and were ground with a mortar 
in a frozen environment with liquid nitrogen to prevent thawing of the samples, 
resulting in tissue powder. For mouse, brains were quickly dissected on an ice-cold 
plate and the different structures stored at -80°C. Human and mouse extracts were 
prepared by homogenizing the brain areas in ice-cold extraction buffer (20 mM HEPES 
pH 7.4, 100 mM NaCl, 20 mM NaF, 1% Triton X-100, 1 mM sodium orthovanadate, 1μM 
okadaic acid, 5 mM sodium pyrophosphate, 30 mM β-glycerophosphate, 5 mM EDTA, 
protease inhibitors (Complete, Roche, Cat. No 11697498001)). Homogenates were 
centrifuged at 15000g for 15 min at 4°C. The resulting supernatant was collected, 
and protein content determined by Quick Start Bradford kit assay (Bio-Rad, 500-
0203). Between 10 and 20 μg of total protein were electrophoresed on 10% SDS-
polyacrylamide gel, transferred to a nitrocellulose blotting membrane (Amersham 
Forward 5’-tgggacgcaaggcgccgtg-3’
Reverse 5’-tggaaggac�gagggactc-3’
Forward 5’-gatcggcca�gaacaagatg-3’
Reverse 5’-agagcagccga�gtctg�g-3’
Forward 5’-actaagtcatcgcgatggagc-3’
Reverse 5’-cgaaatcgtctagcgcgtcgg-3’
Forward 5’-catggtcaggtcatggatgacc-3’
Reverse 5’-taatcagccactgatccacccag-3’
Forward 5’-ggacg�tgacatgcactcac-3’
Reverse 5’-cactctggctacatggtagcat-3’
Forward 5’-tggcatccatgc�gtgtat-3’
Reverse 5’-cgcgtcgagaag�ccta�-3’
CPEB4 (-)
R6/1
zQ175
tTA
BitetO
CPEB4 (+)
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Protran 0.45 μm, GE Healthcare Life Sciences, 10600002) and blocked in TBS-T (150 
mM NaCl, 20 mM Tris–HCl, pH 7.5, 0.1% Tween 20) supplemented with 5% non-fat 
dry milk. Membranes were incubated overnight at 4°C with the primary antibody in 
TBS-T supplemented with 5% non-fat dry milk, washed with TBS-T and next incubated 
with secondary HRP-conjugated anti-mouse IgG (1:2000, DAKO, P0447), anti-rabbit 
IgG (1:2000, DAKO, P0448), anti-goat IgG-Fc fragment (1:4000, Bethyl, A110-104P) 
or anti-rat IgG-Fc fragment (1:5000, Bethyl, A110-136P) and developed using the ECL 
detection kit (PerkinElmer, NEL105001EA).
Antibodies: Rabbit CPEB1 (1:350, Santacruz, sc-33193); rabbit CPEB2 (1:1000, 
Abcam, ab51069); rabbit CPEB3 (1:1000, Abcam, ab10883); rabbit CPEB4 (1:1000, 
Abcam, ab83009); rabbit AUTS2 (1:750, Sigma, HPA000390); mouse STX6 (1:1000, BD 
transduction laboratories, Cat. No. 610635), mouse TAU-5 (1:1000, Merck Milliporte, 
Cat. 577801), mouse GSK3α/β (1:1000, ThermoFisher scientific, Cat. 44–610), mouse 
α-SYN (1:1000, Abcam, [4D6] ab1903); rabbit KTN1 (1:1000, Proteintech, Cat. 19841-
1-AP). rabbit PTEN (1:1000, Cell Signaling, 9559S); mouse DYRK1A (1:1000, Abnova, 
H00001859-M01); rabbit FOXP1 (1:2000 for mouse and 1:500 for human samples, 
Abcam, ab16645); rabbit WAC (1:500, Merk Millipore, ABE471); mouse RBFOX1 
(1:2000 for mouse and 1:1000 for human samples, Merk Millipore, MABE985), rabbit 
PCDH9 (1:500, Abcam, ab171166); rabbit ZBTB20 (1:300, SantaCruz, sc-99728); rabbit 
TNRC6B (1:500, Merk Millipore, AB9913); rat CHD2 (1:750, Merk Millipore, MABE873); 
rabbit GPC6 (1:1000, Abcam, ab136295); mouse β-GAL (1:3000, Promega, Z378A); 
mouse β-ACTIN (1:25000, Sigma, A2228).
2.3. Real-time quantitative reverse transcriptase-PCR
Total tissue RNA was extracted from frontal Cx - BA8/9 of ASD and CTRL subjects, 
St and Cx of HD and CTRL subjects, St and Cx of WT and R6/1 mice WT and, Control, 
CPEB4 GT/+ and TgCPEB4∆4 mice using the Maxwell® 16 LEV simplyRNA Tissue Kit 
(Promega, AS1280). The resulting total RNA was used for cDNA synthesis with a 
Super Script III First-Strand Synthesis SuperMix kit (Invitrogen, PN 11752250) with 
the amplification protocol 30” at 95°C + (5” at 95°C + 5” at 60°C) x 40 + (5” at 60°C + 
5” at 95°C). Quantification was performed by real-time PCR using a CFX 384 System 
(Bio-Rad) in combination with SsoFast Eva Green (Bio-Rad, #1725204) and 0.25μM of 
primer pair was used. Data were analyzed by GenEx 5.3.7 software (Multid AnaLyses 
AB). The mRNA levels were normalized first relative to total RNA and then relative to 
the 18S ribosome subunit, β-ACTIN, GAPDH and β-TUBULIN gene expression in each 
sample.
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Absolute quantitative PCR was performed to determine the percentage of each 
CPEB4 splicing isoform in both human and mouse species using specific primers. 
For every primer couple, specificity was tested by PCR-mediated amplification of 
specific amplicons from each isoform. No product was detected in any non-specific 
combination. Amplicons of each CPEB4 isoform were serially diluted to generate a 
calibration curve. Next, total tissue RNA was extracted, and quantitative real-time 
RT-PCR was performed. Finally, the percentage of each CPEB4 isoform with respect to 
total CPEB4 copies was calculated.
Human primers
Forward 5’-ggcagccatc�gaacga-3’
Reverse 5’-aagtcacacgaccagaacca-3’
Forward 5’-gcctcataaagcagaaagcaa-3’
Reverse 5’-agcatcaatgagtgcctgaa-3’
Forward 5’-gaacgctactctagaaaggtg�tg-3’
Reverse 5’-cgaaagctggcagtgatct-3’
Forward 5’-cactg�tccaatggaagatgg-3’
Reverse 5’-ggtgaacccaggccactatg-3’
Forward 5’-agctgaaaatgatacca�aaagcaa-3’
Reverse 5’-cca�ggaaacagtgaagactgac-3’
Forward 5’-atccgatagctctctgc�a�aatggt-3’
Reverse 5’-cacggccatcatccaagaat-3’
Forward 5’-agctgaaaatgatacca�aaaggtca-3’
Reverse 5’-aggctgatccccacggc-3’
Forward 5’-gtctaaacta�catatccaggatccg-3’
Reverse 5’-cctctcc�cgcccatatgtc-3’
Forward 5’-gaagcggagagagtccacct-3’
Reverse 5’-tcctgaggc�aagtgctacatc-3’
Forward 5’-atcca�ggagggcaagtc-3’
Reverse 5’-gctcccaagatccaactacg-3’
CPEB4∆4
CPEB4∆3∆4
Full Length 
CPEB4
AUTS2
18S
CPEB1
CPEB2
CPEB3
 Total 
CPEB4
CPEB4∆3
Mouse primers
Forward 5’-�atctgcagctcacaacctg-3’
Reverse 5’-gcaaaagtac�gaagcagacct-3’
Forward 5’-ctgcagcagaggaactcgta-3’
Reverse 5’-gg�gctccaaggagactgt-3’
Forward 5’-aaaacccagccccagtct-3’
Reverse 5’-gc�ggggatctctgagga-3’
Cpeb2
Cpeb3
Cpeb1
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Forward 5’-caaatc�a��ccaccaaaagg-3’
Reverse 5’-catcaatgagagcctgaacaga-3’
Forward 5’-agctgaaaatga�cca�aaagcaa-3’
Reverse 5’-ccatcggaaacaatgaagactgac-3’
Forward 5’-atccgatag�ctctgc�a�aatggt-3’
Reverse 5’-acggccatcatccaggaat-3’
Forward 5’-gctgaaaatga�cca�aaaggtca-3’
Reverse 5’-gagg�gatccccacggc-3’
Forward 5’-ctaaacta�catacccaggatccg-3’
Reverse 5’-cctctcc�cgcccataagtc-3’
Forward 5’-cctccaggccctagtctc�-3’
Reverse 5’-aaggggtcccagtaggatgt-3’
Forward 5’-cggggtgctgaagaacat-3’
Reverse 5’-ctccaactcgtgagagaaatcat-3’
Forward 5’-agggaacatccatcacaagc-3’
Reverse 5’-tggactctgtcc�gaagtcc-3’
Forward 5’-ggcagcaaggtaaccacagt-3’
Reverse 5’-gatggcaaccag�ctccag-3’
Forward 5’-tggcagtgaggc�atga-3’
Reverse 5’-gc�caggctcatagtct-3’
Forward 5’-ctcaacacgggaaacctcac-3’
Reverse 5’-cgctccaccaactaagaacg-3’
Forward 5’-ctaaggccaaccgtgaaaag-3’
Reverse 5’-accagaggcatacagggaca-3’
Forward 5’-ctcccactc�ccacc�cg-3’
Reverse 5’-cataccaggaaatgagc�gacaa-3’
Forward 5’-gacctatcatggggacagtga-3’
Reverse 5’-cggctctgggaacatag�t-3’
β-Actin
Gapdh
β-Tubulin
Gsk3 β
Snca
18s
Cpeb4∆4
Cpeb4∆3∆4
Full Length 
Cpeb4
Auts2
Stx6
Mapt 
Total Cpeb4
Cpeb4∆3
Human and mouse common primers
Forward 5’-�gctcca��tctgtgctaa-3’
Reverse 5’-agcagcccagcaata�cac-3’
Total 
CPEB4
2.4. Histopathology tissue analysis. Immunohistochemistry and 
immunofluorescence
For human samples, formalin-fixed (4%, 24 h), paraffin-embedded tissue from Cx 
and St were used. Sections (5 μm thick) were mounted on superfrost-plus tissue slides 
(Menzel-Gläser, 631-9483) and deparaffinized. Peroxidase activity was quenched with 
0.3% H2O2 in methanol for 30 min, followed by antigen retrieval with 10 mM pH 6.0 
citrate buffer heated by microwave for 15 min.
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Mice euthanasia was performed using CO2. Brains were immediately removed 
and dissected on an ice-cold plate and left hemispheres, processed for histology, were 
placed in 4% paraformaldehyde (PFA) in Sorensen’s phosphate buffer overnight and 
then immersed in 30% sucrose in phosphate buffered saline (PBS) for 72 h. Once 
cryoprotected, the samples were included in optimum cutting temperature (OCT) 
compound (Tissue-Tek, Sakura Finetek Europe, ref. 4583), frozen and stored at -80°C 
until use. 30 µm sagittal sections were cut on a cryostat (Thermo Scientific), collected 
and stored free floating in glycol containing buffer (30% glycerol, 30% ethylene glycol 
in 0.02 M phosphate buffer) at -20°C. Before staining, sections were washed with PBS 
to eliminate the cryoprotective buffer and immersed in 0.3% H2O2 in PBS for 30 min 
to quench endogenous peroxidase activity.
For immunohistochemistry staining, sections were immersed for 1h in blocking 
solution (PBS containing 0.5% Fetal Bovine Serum, 0.3% Triton X-100 and 1% BSA 
and incubated overnight at 4°C with the corresponding primary antibody diluted in 
blocking solution. After washing, brain sections were incubated first with biotinylated 
anti-rabbit or anti-mouse secondary antibody and then with avidin-biotin complex 
using the Elite Vectastain kit (Vector Laboratories, PK-6101-2). Chromogen reactions 
were performed with diaminobenzidine (SIGMAFAST DAB, Sigma, D4293) for 10 
min. Mouse sections were mounted on glass slides and coverslipped with Mowiol 
(Calbiochem, Cat. 475904) while human slides were dehydrated and coverslipped 
with DePex (Serva). Images were captured using an Olympus BX41 microscope with 
an Olympus camera DP-70 (Olympus Denmark A/S). 
Antibodies: Rabbit CPEB4 (1:1000, AVIVA, ARP41024_P050); monoclonal mouse 
CPEB4 (1:100 and 1:1500 in human and mouse tissue respectively, generated by 
Mendez R. Lab); rabbit KTN1 (1:100, Proteintech, Cat. 19841-1-AP).
For immunofluorescence, sections were pretreated with 0.1% Triton X-100 for 30 
min, 1 M glycine for 15 min and blocking solution (1% BSA, 0.3% FBS and 0.1% Triton 
X-100) for 1 h. Sections were then incubated overnight at 4 °C with monoclonal mouse 
anti CPEB4 (1:1000, generated by Mendez R. Lab) and goat anti huntingtin (1:200, N-18 
Santacruz, sc-8767) in blocking solution. The following day, sections were washed 
in PBS and incubated with secondary antibodies for 2 h: anti-goat-Alexa 555 (1:500, 
ThermoFisher, A-21432) and anti-mouse-biotin (from Elite Vectastain kit, Vector 
Laboratories, PK-6102), followed by signal amplification with Streptavidin-Alexa488 
(1:500, ThermoFisher, S32354) for 1h. After washing, nuclei were counterstained 
with DAPI (1:5000, Calbiochem, 28718-90-3). Finally, sections were mounted on 
glass slides, coverslipped with Mowiol (Calbiochem, 475904) and maintained at 4°C. 
101
VII. MATERIALS AND METHODS
Images were acquired with a laser confocal LSM710 system coupled to the invert 
Axioobserver microscope with a 63×, 1.4 numerical aperture oil-immersion objective 
using the Zen2010B sp1 software (Carl Zeiss). Sequential optic sections (1 μm) were 
acquired in z stacks. Images were processed using ImageJ 1.45s.
2.5. Poly(U) chromatography
Mouse samples: WT and R6/1 mice 7.5 month-old (n=4); WT, CPEB4 GT/+ and 
CPEB4 KO (n=2); control and TgCPEB4∆4 mice (n=3) 1.5 month-old were sacrificed by 
cervical dislocation. St in the case of WT versus R6/1 mice and Cx and St together in 
all other cases were quickly dissected on an ice-cold plate.
 Human samples: brain specimens from frontal cortex - BA8/9 of ASD patients 
(n=6) and controls (n=5) with age between 5-23 years old.
Human and mouse samples were homogenized and total RNA was extracted 
using the Maxwell® 16 LEV simplyRNA Tissue Kit (Promega, AS1280), and stored at 
-80°C until use. The poly(A) RNA fraction was purified by poly(U) chromatography. 
Poly(U)-agarose (Sigma, p8563) was suspended in swelling buffer (0.05 M Tris-HCl, pH 
7.5, 1 M NaCl) 35 ml/g, incubated overnight at room temperature and loaded into the 
chromatography column. An aliquot of total RNA was stored at -80°C (“Input”) and the 
rest was incubated with sample buffer (0.01 M Tris-HCl, pH 7.5, 1 mM EDTA, 1% SDS) 
for 5 min at 65°C and chilled on ice. Binding buffer was added (0.05 M Tris-HCl, pH 
7.5, 0.7 M NaCl, 10 mM EDTA, 25% [v/v] formamide) and then the sample was loaded 
into the poly(U)-agarose chromatography column (Mobitec, M1002s) and incubated 
for 30 min at room temperature (25°C) with agitation. Next, the column containing 
the sample was washed three times at 25°C and six times at 55°C with washing 
buffer (0.05 M Tris-HCl, pH 7.5, 0.1 M NaCl, 10 mM EDTA, 25% [v/v] formamide). 
The 55°C washes were collected and stored at -80°C (“Short poly(A)-tail fraction”). 
The remaining poly(A) RNA (“Long poly(A)-tail fraction”) was eluted with elution 
buffer (0.05 M HEPES, pH 7, 10 mM EDTA, 90% [v/v] formamide) at 55°C and stored 
at -80°C. The RNA of the two poly(A) fractions was precipitated by adding 1 volume 
of isopropanol, 1/10th volumes of sodium acetate 3 M pH 5.2 and 20 µg of glycogen 
(Sigma, G1767). The samples were incubated at -20°C for 20 min and centrifuged 
15 min at 14000g at 4°C. The supernatant was removed and the pellet was washed 
with 750 µL of ethanol and centrifuged at 14000g and 4°C for 5 min. The supernatant 
was removed and the pellet was air-dried for 5 min. The RNAs were resuspended in 
300 µL of nuclease-free water and then 300 µL of acid Phenol:Chloroform (5:1) were 
added to them. Samples were vortexed and centrifuged for 10 min at 14000g and 4°C. 
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The aqueous phase was recovered, mixed with 1 volume of chloroform, vortexed and 
centrifuged again. The aqueous phase was recovered and precipitated again using the 
isopropanol precipitation.
2.6. RNA immunoprecipitation
WT and R6/1 mice (n=4) were sacrificed by cervical dislocation at the age of 7-8 
months. Total St was quickly dissected on an ice-cold plate and cut into pieces. The 
pool of the four WT or R6/1 striata was washed twice with PBS, crosslinked with 0.5% 
PFA in PBS for 7 min at room temperature and treated with glycine 1M for 5 min. 
After two washes with cold PBS, pool samples were homogenized in lysis buffer (50 
mM Tris, pH 8.0, 150 mM NaCl, 1% NP-40, 0.5% deoxicolate, 0.1% SDS, 1 mM EDTA, 
protease inhibitor (Complete, Roche, 11697498001), RNAse inhibitor (Ribolock, Life 
Technologies, EO0381)) and centrifuged at 13000 g for 10 min at 4°C. Dynabeads 
protein A (Life Technologies, 10001D) were washed twice with PBS and incubated with 
anti-CPEB4 antibody (10 μg, Abcam, ab83009), anti-CPEB1 antibody (5 μg, Proteintech, 
13274-1-AP) or rabbit IgG (5 μg, Sigma, I5006) for 2h. Next, dynabeads were washed 
once with PBS and twice with triethanolamine 0.2M pH 8.2, incubated with dimethyl 
pimelimidate 20 mM for 30 min, treated with Tris 50mM pH 8.0 and washed twice 
with lysis buffer. Lysates were precleared with unconjugated dynabeads for 20 min at 
4°C in a wheel, an aliquot was stored at -80°C (“Input”) and the rest of the extract was 
immunoprecipitated with the antibody-conjugated dynabeads overnight at 4°C in a 
wheel. Immunoprecipitates were washed six times in cold lysis buffer. 
For protein extraction, samples were incubated with Laemmli buffer (10% SDS, 
0.325 M Tris HCl pH7.5, Glycerol 25%) for 20 min at 60°C. Dynabeads were removed 
with the help of a magnet and samples were boiled after adding DTT 0.1 M and 
bromophenol blue 0.1%. 
For RNA extraction, immunoprecipitates were resuspended in 100µl of proteinase 
K buffer (200 mM Tris pH 7.5, 100 mM NaCl, 10 mM EDTA, 1% SDS) containing 0.7 µg/µl 
of proteinase K (Roche, 03115852001) and incubated 1h at 42°C and 1h at 65°C. RNA 
was extracted using the TRIzol reagent (Invitrogen, 15596018). Briefly, samples were 
resuspended in 300 µl of TRIzol. Then, 20 µg of glycogen was added. Samples were 
vortexed, incubated for 5 min at room temperature and centrifuged at 14000g for 15 
min at 4°C. The aqueous phase was recovered, mixed with 1 volume of isopropanol, 
incubated for 5 min at room temperature and precipitated at 14000g 30 min at 4°C. 
The pellet was washed with 300 μl of ice-cold 75% ethanol and centrifuged at 14000g 
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10 min at 4°C. The pellets were resuspended in 100 μl of nuclease-free water. To 
ensure the complete removal of the phenol, the RNA was precipitated again. To this 
aim, 10 μl of sodium acetate 3 M pH 5.6 and 250 μl of 75% ethanol were added. 
Samples were vortexed and stored at -20°C for 1h. Then, they were precipitated at 
14000g for 30 min at 4°C. The pellet was washed with 75% ethanol and centrifuged 
again at 14000g for 10 min at 4°C. Pellets were air-dried for 5 min and resuspended 
in nuclease-free water.
2.7. Poly(A) test assay
Total mRNA from a pool of 2 St from control and TgCPEB4∆4 was extracted 
using GenElute mRNA Miniprep Kit (Sigma, MRN70) and treated with DNaseI 
(TURBO DNA-free, Thermo Fisher Scientific, AM1907) following the manufacturer’s 
recommendations. 6 μg of this mRNA was incubated for 30 min at 37°C with 20 µM 
of an oligo dT primer and 0.2U of RNase H (New England Biolabs, M0297S) or H2O, 
and purified using Phenol/Chloroform extraction. 4 μg of RNA were ligated to 0.4 
μg of SP2 anchor primer using T4 RNA ligase (New England Biolabs, M0204S) in a 
final volume of 10 μl. The whole ligation was retrotranscribed into cDNA using the 
RevertAid First Strand cDNA Synthesis kit (ThermoFisher Scientific, K1621) and 0.4 
μg of ASP2T antisense primer in a final volume of 50 μl. 1 μl of cDNA was amplified 
by PCR using BioTaq DNA polymerase (Bioline, Bio-21040) in a final volume of 50 μl, 
using the forward primers and the reverse primer ASP2T. 
Half of the PCR products were run in a 2% agarose/GelRed gel and run at 120V 
for 1.5h. A picture of the gel was taken together with a ruler so as to know the 
position of the ladder bands after the hybridization. Gels were washed upside-down 
in lysing buffer (1.5M NaCl, 0.5M NaOH) for 30 min, briefly washed 3 times with 
ddH2O and incubated in neutralization buffer (1.5M NaCl, 1M Tris-HCl pH 7.4) for 45 
min. DNA was transferred overnight to a Biodyne® nylon bidine membrane (0.45µm, 
Pall Corporation, 60102) and cross-linked (254 nm; 0.12 J). The membrane was pre-
hybridized in church buffer (342mM Na2HPO4, 158mM NaH2PO4, 6% [w/v] SDS, 1mM 
EDTA, pH 7.2) for 3h at 55ºC and hybridized overnight with 32P-labeled probes diluted 
in church buffer at 55ºC. The following day, membranes were washed with washing 
buffer (0.1% SDS in SSC 1X) until background signal was removed. Membranes were 
exposed to an autoradiography film and developed.
For the labelling of the probes, 20 pmol of each DNA oligo were labelled with 3 
μl of 32Pγ-ATP 3000 Ci/mmol in a final volume of 10 μl for 30 min at 37ºC using T4 
polynucleotide kinase (New England Biolabs, M0201S). Labelled probes were purified 
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with illustra MicroSpin G-25 columns (GE Healthcare, 27-5325-01) and diluted in 25 
ml of pre-warmed church buffer.
Primers sequence: 
SP2 5’-P-ggtcacctctgatctggaagcgac-NH2-3’
ASP2T 5’-gtcgc�ccagatcagaggtgacc��t-3’
AUTS2 5’-ggaca�aaccctc�gtctacata�tgg-3’
2.8. High-Resolution poly(A) tail (Hire-PAT) assay
To confirm the poly(A) tail length measured by polyU chromatography and by 
PAT assay, the USB® Poly(A) Tail-Length Assay Kit (Affimetrix, catalog 76455) based 
on Hire-PAT method, was used. Total striatal RNA from 1.5 month-old control and 
TgCPEB4∆4 mice (n=3) was extracted using the Maxwell® 16 LEV simplyRNA Tissue Kit 
(Promega, AS1280) and stored at -80ºC until use. G/I tailing (1 μg of total RNA) and 
reverse transcription were performed according to the manufacturer’s instructions. 
Poly(A) size was determined by subtracting the PCR amplicon size obtained with the 
Universal primer and Auts2 forward specific primers.  To verify that the measured 
poly(A) tail corresponds to Auts2, three different forward specific primers were 
tested. PCR products were resolved on 2.5% agarose/gelgreen (Biotium, 41004) gels 
run at 120V for 1.5h.
Primer sequences: 
Auts2 -F1 5’-�tggagagaatatgac�tactagccgag-3’
Auts2 -F2 5’-aaatacactatatc�gtctactggcctg-3’
Auts2 -F3 5’-cca�tggtcctctagtata�aaagtgc-3’
Auts2 -R 5’-gaaaataaaacaaaacaaaaaacaggataacaatg-3’ 
2.9. Generation of TgCPEB4∆4 mice
Human CPEB4 lacking exon 4 (CPEB4Δ4, without 8 aminoacids) cDNA was cloned 
into a plasmid containing a bidirectional TetO sequence flanked by CMV minimal 
promotors with lacZ reporter sequences coupled to a nuclear localization signal 
(pBI-G, Clontech, 631004) and microinjected into single-cell CBAxC57BL/6 embryos. 
Founder mice were then backcrossed with WT C57BL/6J mice (TetO βGal/CPEB4∆4). 
TetO βGal/CPEB4∆4 was crossed with CamkII-tTa (Tta) mouse line (Mayford et al., 
1996) to obtain the conditional transgenic mice with forebrain neural specific CPEB4∆4 
overexpression mice (TgCPEB4∆4 mice).
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2.10. Golgi Staining
Three month-old mice were completely anesthetized with an intraperitoneal 
pentobarbital injection (60 mg/kg Dolethal®, Vetoquinol). The whole brain was 
extracted and immersed in Golgi-Cox staining solution (FD Rapid GolgiStainTM 
kit, FD Neurotechnologies, cat. PK401). 150 µm sagittal sections were obtained in 
a Leica VT1200S vibratome and mounted on gelatin-coated slides. Golgi staining 
was performed as manufacturer’s instructions. Afterwards, all sections were 
counterstained with toluidine blue pH 4.0 (1 g/l Toluidine Blue (Sigma, 198161), 0.8 
M glacial acetic acid) and coverslipped with DePeX (Amsbio, 18243.02). 
Pyramidal neurons from layer II/III of the cortex were identified by their distance 
from pia mater and their distinct morphologies. Secondary, tertiary and quaternary 
dendrites of these neurons were selected for analysis. Z-stacks of the entire apical 
dendritic tree of Golgi stained pyramidal neurons (up to 80 μm total on Z-axis, optical 
section thickness = 0.5 μm) were taken at 40x magnification with 2x optical zoom 
on a vertical Zeiss Axio Imager.Z1 M. Spine density, length and classification were 
performed according to (Risher et al., 2014), unbiased blinded to genotype.
2.11. Brain weight and volumetric analysis
1.5 month-old mice were completely anesthetized with an intraperitoneal 
pentobarbital injection (60 mg/kg Dolethal®, Vetoquinol). The whole brain was 
extracted and weight in a precision scale (Metter Toledo, AB265-S). Left hemispheres 
were fixed in 4% paraformaldehyde, immersed in 30% sucrose, included in OCT 
compound (Tissue-Tek, Sakura Finetek Europe, 4583), frozen and stored at -80°C. 
Sagittal sections (30 µm thick) were cut on a cryostat and every sixth section was 
counterstained with toluidine blue pH 4.0 (1g/l Toluidine Blue (Sigma, 198161), 0.8 M 
glacial acetic acid). Digital images were captured at a 2.5x magnification (Canon EOS 
450D digital camera) and the hippocampal, striatal and motor and somatosensory 
cortical area from 20-22 sections for each animal was calculated by means of the 
ImageJ software (Schneider et al., 2012). Considering a separation of 180 μm between 
each section, total structure volume in each mouse was calculated. 
2.12. Electrophysiology
For preparation of brain slices, we based on the N-methyl-D-glucamine (NMDG) 
protective recovery method described by the lab of Guoping Feng (Ting et al., 2014). 
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Briefly, 5-6 weeks old control (n=5) and TgCPEB4∆4 (n=5) mice of both sexes were 
anesthetized with 2% tribromoethanol (0.15 ml/10 mg) and rapidly decapitated. The 
brains were dissected out and transferred to NMDG ice-cold artificial cerebrospinal 
fluid (ACSF) composed of: 93mM NMDG, 2.5mM KCl, 1.2mM NaH2PO4, 30nM 
NaHCO3, 25mM D-glucose, 20mM HEPES, 5mM Na-ascorbate, 2mM thiourea, 3mM 
Na-pyruvate, 10mM MgSO4, and 0.5mM CaCl2. The pH of the solution was titrated 
to pH 7.3-7.4 with concentrated HCl (osmolality 310-315 mOsmol·kg-1) and bubbled 
with carbogen (5% CO2 - 95% O2). 350 μm coronal slices were cut on a Vibratome 
VT1200S (Leica) and transferred for initial recovery to NMDG ACSF at 33 ± 1°C. Finally, 
slices were placed in a holding chamber at room temperature with normal ACSF 
composed of: 126mM NaCl, 2.5mM KCl, 2mM CaCl2, 2mM MgCl2, 1.25mM NaH2PO4, 
26mM NaHCO3, and 10mM D-glucose (osmolality 305–315 mOsmol·kg
-1), pH 7.4, 
when bubbled with carbogen (5% CO2–95% O2).
For whole-cell patch-clamp recordings, slices were transferred into a recording 
chamber that was perfused with 33 ± 1°C bubbled ACSF at 2–3 ml/min. Pyramidal 
neurons of the somatosensory cortex were visualized by a Nikon Eclipse FN1 
microscope, a 40x water immersion objective (Nikon), and a USB 2.0 monochrome 
camera (DMK 31BU03.H, TheImagingSource). Whole-cell recordings were performed 
using a double patch clamp EPC10 plus amplifier (HEKA). Under voltage-clamp 
conditions, the patch-pipettes for excitatory postsynaptic currents recording (EPSCs) 
contained: 120mM K-gluconate, 10mM KCl, 10mM phosphocreatine disodium salt, 
2mM MgATP, 0.3mM NaGTP, 0.1mM EGTA, 10mM HEPES, pH 7.2 adjusted with 
KOH, osmolality 280-290 mOsmol·kg-1. Recording of miniature EPSCs (mEPSCs) were 
done in the presence of tetrodotoxin (1 μM) and picrotoxin (50 µM) to block sodium 
channels and GABAA receptors, respectively. Cells were held in voltage-clamp mode 
at a holding potential (Vhold) of -70 mV, while resistance was compensated by 70% 
(lag 10 μs). Recordings were discontinued if series resistances increased by > 50% or 
exceeded 15 MΩ. 
Currents were low-pass filtered at 3 kHz, digitized at 20 kHz, and acquired using 
PatchMaster software (HEKA). All miniature postsynaptic currents were analyzed with 
the program Stimfit (Guzman et al., 2014). Recordings were first digitally filtered at 1 
kHz. For each cell, all events were inspected to avoid false-positive events, and then 
an average of all events detected was made.
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3. MOUSE BEHAVIORAL TEST
3.1. Body Weight (BW)
Starting at 2 weeks of age, mice were weighed every weeks in in a precision scale 
(AND, EK-3000i).
3.2. Open Field (OF)
Locomotor activity was measured at the age of 5 weeks in TgCPEB4∆4 mice 
in clear Plexiglas® boxes measuring 27.5 cm x 27.5 cm, outfitted with photo-beam 
detectors for monitoring horizontal and vertical activity. Activity levels were recorded 
with a MED Associates’ Activity Monitor (MED Associates, St. Albans, VT) and were 
analyzed with the MED Associates’ Activity Monitor Data Analysis software. Mice 
were placed in the center of the open-field apparatus and left to move freely. Data 
were individually recorded for each animal during 15 min. Distance walked in the 
periphery of the box (3.5 cm from the edges) was measured.
3.3. Ultrasonic Vocalization (UsV)
UsV was measured at the age of 3, 6, 9 and 12 postnatal days in TgCPEB4∆4 
mice. Dam was removed from a temperature-controlled home cage where the pups 
remained. Then, pups were removed individually and placed in a plate equipped to 
record UsV for 5 min (Avisoft Recorder). To avoid potential confounding effects due to 
temperature, the room was maintained at 21°C and body temperature was measured 
with an axillary probe after the 5 min test. UsV was analyzed with Avisoft SASLab Pro 
software.
3.4. Social Approach (SAp)
SAp was examined at the age of 5 weeks in TgCPEB4∆4 mice. The first day 
(training), mice were allowed to explore an empty Plexiglas® box measuring 45 
cm x 45 cm during 10 min. The next day (test), mice were placed in the same box 
containing two wire cages placed in opposite corners, one empty and the other with 
an unknown (gender paired) mouse on it. Mice were recorded during 10 min and the 
time expended interacting with each cage was measured.
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3.5. Elevated plus maze (EPM)
Anxiety-like behavior was examined at the age of 5 weeks TgCPEB4∆4 mice. 
Animals were tested in a 5-min single trial EPM in which the mouse was allowed 
to move freely along the apparatus under a constant intense white light. Animal 
movement was recorded and the total time spent standing or walking on the open 
and closed arms was measured. The criterion was the head, forelimbs and hindlimbs 
being placed on open or closed arms. Our maze consists of four arms (two open 
without walls and two enclosed by 15 cm high walls) 26 cm long and 5 cm wide. It is 
elevated 40 cm off the floor it is on.
4. BIOINFORMATICS AND DATA ANALYSIS
4.1. Microarrays analysis of poly(U) chromatography
cDNA Library preparation and amplification were performed according to the 
manufacturer’s (Sigma-Aldrich) instructions for the WTA2 kit from 25 ng starting 
material. The cDNA was amplified for 17 cycles and purified using PureLink Quick PCR 
Purification Kit (Invitrogen, K310001). Quantification of amplified cDNA was done on 
a Nanodrop ND-1000 spectrophotometer (Thermo-Fisher Scientific, Waltham). 8.5 ug 
of the cDNA from each sample were fragmented and labeling with GeneChip Mapping 
250 K Nsp assay kit (Affymetrix, 900753) following the instructions of manufacturer. 
Human: samples ready to hybridize were denatured at 99°C for 2 min prior to incubation 
into the GeneChip Human PrimeView arrays (Affymetrix, 901838). Hybridization 
was performed for 16 h at 45 °C / 60 rpm in the GeneChip Hybridization Oven 645 
(Affymetrix, 00-0331). Washing and stain steps after hybridization were performed 
in the GeneChip Fluidics Station 450 (Affymetrix, 00-0079), following the specific 
script for PrimeView arrays. Finally, the arrays were scanned with GeneChip Scanner 
GCS3000 (Affymetrix) using default parameters, and the generation of CEL files for 
bioinformatics analysis was done with Command Console software (Affymetrix). 
Mouse: hybridization was performed using the GeneAtlas Hyb, Wash and Stain Kit for 
3’ IVT arrays. 
Samples ready to hybridize were denatured at 96°C for 10 min prior to incubation 
into Mouse MG-430 PM Array Strip (Affymetrix, 901570), the hybridization was 
performed for 16 h at 45°C in the GeneAtlas Hybridization Oven (Affymetrix, 00-
0331). Washing and Stain steps after hybridization were performed in the GeneAtlas 
Fluidics Station (Affymetrix, 00-0079), following the specific script for Mouse MG-
430 PM Arrays. Finally, the arrays were scanned with GeneAtlas Scanner (Affymetrix) 
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using default parameters, and the generation of CEL files for bioinformatics analysis 
was done with GeneAtlas software (Affymetrix).
Processing of microarray samples was performed using R (R Development Core 
Team, 2014) and Bioconductor (Gentleman et al., 2004). Raw CEL files were normalized 
using RMA background correction and summarization (Irizarry et al., 2003). Standard 
quality controls were performed in order to identify abnormal samples regarding: 
a) spatial artifacts in the hybridization process (scan images and pseudo-images 
from probe level models); b) intensity dependences of differences between chips 
(MvA plots); c) RNA quality (RNA digest plot); and d) global intensity levels (boxplot 
of perfect match log-intensity distributions before and after normalization and RLE 
plots). No samples were discarded due to poor quality. Probeset annotation was 
performed using the information available in Affymetrix web page (https://www.
affymetrix.com/analysis/index.affx) using version na35.
Expression values were adjusted for technical biases as described in (Eklund and 
Szallasi, 2008) using a linear model and implemented with the R package “limma” 
(Ritchie et al., 2015). For each biological replicate the log2 fold change was computed 
between “WASH” and “ELUTED” samples and used to find significant differences 
between WT vs CPEB4 GT/+ and CPEB4 KO mice (n=2), Control vs. TgCPEB4∆4 (n=3) 
and control (n=5) vs ASD patients (n=6). Differential expression was performed using 
a linear model with fluidics and amplification batch as covariates. P-values were 
adjusted with the Benjamini and Hochberg correction.
In the case if WT vs R6/1 mice value ≤ -1.5 in at least one probe means that 
the transcript is shortened in R6/1 mice, ≥ 1.5 means that is lengthened and the 
values in between mean no change.  In all other cases, we considered one transcript 
is shortened when p-value < 0.05 and f.c. is negative and lengthened when p-value < 
0.05 and f.c. is positive, in at least one probe. If the same transcript showed opposite 
results for different probes, it was considered as not changed.
4.2. Microarrays analysis of RNA immunoprecipitation
Input and immunoprecipitated RNA were purified using Agencourt RNAClean XP 
bead suspension (Beckman Coulter, A66514). Library preparation and amplification 
were performed following the distributor’s (Sigma-Aldrich) recommendations for 
WTA2 from purified immunoprecipitated or diluted input RNA. SYBR Green (Sigma-
Aldrich, 163795-75-3) was added to the amplification reaction, which was performed 
in a CFX Real-time instrument (Bio-Rad) to monitor amplification yield. When the SYBR 
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Green signal reached a plateau after 27 cycles, the reaction was stopped. Amplified 
cDNA was purified and quantified on a Nanodrop ND-1000 spectrophotometer 
(Thermo-Fischer). 8 µg of cDNA were subsequently fragmented by DNAseI and 
biotinylated by terminal transferase obtained from GeneChip Mapping 250K Nsp 
Assay Kit (Affymetrix, 900753). After hybridization for 16h at 45°C, washing and 
staining was performed in the Affymetrix GeneAtlas Fluidics Station. The arrays were 
scanned in the GeneAtlas Imaging Station. All processing was performed according 
to manufacturer’s recommendations. CEL files were generated from DAT files using 
Affymetrix Command Console software. To generate the log2 expression estimates, 
overall array intensity was normalized between arrays and the probe intensity of all 
probes in a probe set summarized to a single value using Robust Multiarray Average 
(RMA) algorithm (Irizarry et al., 2003).
In order to compare samples from different conditions, fold changes were 
computed after MA mean and variance normalization using a Generalized Additive 
Model (GAM). An empirical Bayes partial density model was then used to compute 
the posterior probability of differential expression. Differentially expressed genes 
were defined as those with a maximum False Discovery Rate (FDR) of 5% and a log2 
fold change threshold of 1.75.  We calculated the Input vs. Eluted f.c. for CPEB1 and 
CPEB4 binders considering a transcript positive when at least one probe showed a f.c. 
above 1.75 in WT or R6/1 mice.
4.3. Gene Ontology analysis
CPEB4 coimmunoprecipitated mRNAs from RWP-1 cells (Ortiz-Zapater et al., 
2011)  and transcripts with changes in their poly(A) tail length in St of symptomatic 
R6/1 mice (f.c. ≤ -2 or ≥ 2) were analyzed with DAVID Bioinformatics Resources 6.7, 
KEGG pathway annotation (Huang da et al., 2009). 
4.4. Analysis of CPE sequences
The longest 3’UTR sequences from selected gene sets were extracted from 
Ensembl (http://www.ensembl.org/) (Yates et al., 2016) and ncbi gene (https://
www.ncbi.nlm.nih.gov/gene). Incidence of functional CPE sequences, Hex and PBE 
(pumilio binding element) sequences in the 3’UTR was detected using the algorithm 
described in (Pique et al., 2008) (http://genome.crg.es/CPE/). The list of 1223 genes 
in the group “increased in brain” was obtained from The human protein atlas (http://
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proteinatlas.org/humanproteome/brain). SFARI Cat. 1, 2 and 3 was obtained from 
SFARI database (https://gene.sfari.org/autdb/GS_Home.do) in September 2016. 
ASD39 gene list consists of the 39 genes harboring rare de novo protein disrupting 
mutations identified in two whole exome sequencing studies in simplex ASD (De 
Rubeis et al., 2014; Iossifov et al., 2014). 
4.5. Enrichment and co-expression network analysis of CPEB binders
Enrichment analysis studies use Fisher’s exact test (the hypergeometric test 
is equivalent to a one-sided Fisher’s exact test) to evaluate whether a gene set, in 
this case CPEB4 or CPEB1 binders determined by RIP, is enriched over background, 
providing a p-value and enrichment value. We used curated ASD candidate gene list 
from SFARI AutDB database, referred as ASD SFARI list and a more restrictive, smaller 
ASD only gene list, where genes linked to intellectual disability were removed. The 
gene set (CPEB4 and CPEB1 binders) was also used to study enrichment in functional 
co-expression modules that represent shared pathology in ASD brain. These gene 
modules derived from previous unbiased Weighted Gene Co-expression Network 
Analysis (WGCNA) obtained by gene array (Voineagu et al., 2011) and by RNA-seq 
(Parikshak et al., 2016) studies from ASD postmortem samples.
4.6. Differential expression analysis
RNA-seq data 
CPEBs expression levels in idiopathic ASD (n=43) and control (n=63) postmortem 
prefrontal cortex samples were evaluated from RNA-seq data from (Parikshak et 
al., 2016). Briefly, the paired-end raw reads were mapped to the human reference 
genome assembly GRCh37.73 using Tophat2 (Kim et al., 2013) and the counts were 
quantified using HTSeq (Anders et al., 2015). Gene length, G+C content and library 
size were normalized (referred to as “Normalized FPKM”) using the cqn package in 
R (Hansen et al., 2012). Linear mixed effects (LME) were used, modeling to account 
for effects from biological covariates (condition, age, sex, brain region), technical 
variables related to sample processing (RIN, brain bank, sequencing batch), technical 
variables related to sequencing quality metrics and individual ID was set as a random 
effect accounting for the fact that multiple samples came from the same individual.
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Microarray data
Individual probeset expression values for each selected gene were annotated 
with Annmap webservice (http://annmap.cruk.manchester.ac.uk), using Homo 
Sapiens v84 Primeview Human Gene Array and Mus musculus v84 Mouse Genome 
430A 2.0 databases. Those probesets annotated as ‘reliable’, in which all probes hit 
the genome only once and localize to exons, were preferentially selected for analysis. 
For those genes lacking a ‘reliable’ probeset, the whole group of probesets was 
taken for comparisons. Graph bars were plotted using the mean of RMA normalized 
expression values from the Primeview human gene array in case of human samples 
and Mouse genome 430 PM array in case of mice. The expression values were 
calculated using R and BioConductor packages. Graph bars were plotted using the 
mean of RMA normalized expression values from the Primeview human gene array 
in case of human samples and Mouse genome 430 PM array in case of mice. The 
expression values were calculated using R and BioConductor packages.
4.7. Differential alternative splicing
We computed percent spliced in (PSI) values using Multivariate Analysis of 
Transcript Splicing (MATS, v3.08), which utilizes TopHat2 (Shen et al., 2012) aligned 
reads and a custom splice-junction library. In total, we used 81 control samples and 
82 ASD cortical samples as reported (Parikshak et al., 2016). In order to account for 
the effects of covariates, we utilized PSI values in the linear mixed effects model 
described below for differential splicing analysis:
lme(PSI ~ diagnosis + age + sex + brain_region + sequencing.batch + 
brain.bank.batch + RIN + seqSV1 + seqSV2, rand = ~1|individualID)
Where two sequencing surrogate variables (seqSV1 and seqSV2) were used as 
covariates.
4.8. Human-mouse altered poly(A) tail length geneset comparison
In order to compare transcripts with altered poly(A) tail in ASD patients and 
CPEB4 modified mice, we first converted the gene set from mouse into their human 
orthologs (18649 total orthologos genes) using Ensembl Genes 85 Mus musculus 
GRCm38p4 Biomart (http://www.ensembl.org/biomart/) (Yates et al., 2016). Then 
we calculated the statistical significance of the overlap between genes with poly(A) 
changes in human ASD and CPEB4 modified mice (http://nemates.org/MA/progs/
overlap_stats.html). We considered overlapping when the representation factor is > 
1 and p < 0.05, and dissimilar when the representation factor is < 1 and p < 0.05.
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4.9. Statistics
Statistical analysis was performed with SPSS 21.0 (SPSS® Statistic IBM®). Data 
are represented as Mean ± SEM (Standard Error of the Mean). The normality of the 
data was analyzed by Shapiro-Wilk test. For 2 group comparison, two tail t-Student’s 
test (data with normal distribution) or Mann-Whitney U-test (data with non-normal 
distribution) was performed. For multiple comparisons, data with a normal distribution 
were analyzed by one way-ANOVA test followed by a LSD or a Games Howell post-
hoc test. Statistical significance of non-parametric data for multiple comparisons was 
determined by Kruskal-Wallis test followed by a Mann-Whitney U-test for analysis of 
paired genotypes. A critical value for significance of p < 0.05 was used throughout the 
study.
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VIII. CONCLUSIONS
1. Brain of HD patients and mouse models show a CPEB1/CPEB4 imbalance, 
being CPEB1 levels increased and CPEB4 decreased.
2. 19% of transcripts in R6/1 HD mouse model exhibit altered poly(A) tail length 
which fits concomitant alteration of their encoded proteins. 
3. Polyadenylation changes in R6/1 mice prominently affects Huntington’s-, 
Alzheimer’s- and Parkinson’s disease related genes.
3. The striatal atrophy associated gene KTN1 with multiple CPE sequences in 
its 3’UTR shows poly(A) shorting in R6/1 mice and decreased protein in HD 
mouse and human brain.
4. CPEB4 binding transcripts are enriched in both risk-genes and gene-modules 
involved in ASD. Accordingly, the majority of high confidence ASD genes 
harbor functional CPEs in their 3’ UTR.
5. In idiopathic ASD brains, CPEB4 presents diminished protein levels and 
its mRNA is mis-spliced in favor of the isoform lacking a neuronal-specific 
microexon.
6. Most high-confidence ASD genes are deadenylated and their encoded 
protein levels are decreased in idiopathic ASD brain. 
7. CPEB4 microexon splicing isoform-imbalance in TgCPEB4Δ4 mice is sufficient 
to mimic the deadenylation and diminished protein level of ASD risk genes 
observed in human ASD cases.
8. TgCPEB4Δ4 mice show ASD-like neuroanatomical, electrophysiological and 
behavioral phenotype.
9. Collectively, these results suggest a role of CPEB-mediated altered 
polyadenylation in HD and other neurodegenerative diseases and unravel 
CPEB4 as a new node in ASD gene expression.
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